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1Synopsis.......
A comprehensive summary of the work incorporated in the thesis with the title “STUDIES
ON CHEMICAL ENTITIES OF PHARMACEUTICAL INTEREST” has been described
as under.
[A] STUDIES ON TRIAZOLES
[B] STUDIES ON  PYRIMIDINES
            [C] STUDIES ON MICROWAVE ASSISTED SYNTHESIS OF 5,6-
DIHYDRO-1,3,4-THIADIAZOLOTRIAZOLES
[A] STUDIES ON TRIAZOLES
Triazole nucleus has been found to be potent drug in pharmaceutical industries. It  is endowed
with a variety of biological activities such as hypnotic, anti-inflammatory, CNS depressant,
anticonvulsant, antitubercular, antitumor, fungicidal etc. Due to the emerging role of triazoles in
pharmaceutical chemistry as well as in biochemistry stimulated tremendous interest in the synthesis
of triazoles with better therapeutic potential.
Considering these facts and the increasing importance of 1,2,4-triazole nucleus, synthesis
of some novel thiadiazoles, aminothiadiazoles, thiadiazepines, imidazolinones, dihydrothiadiazoles,
thiadiazine and Mannich bases bearing triazole nucleus has been undertaken. The study is described
in the following parts.
PART-I : STUDIES ON 1,3,4-THIADIAZOLES
The study of thiadiazole derivatives revealed that these are valuable drugs for various
diseases and possess a wide spectrum of biological activities such as antifungal, antibacterial,
anticonvulsant and herbicidal. With the view of above findings, it appeared of interest to synthesise
thiadiazole derivatives with better potency.
SECTION-I : Synthesis and biological evaluation of  3-o-Chlorophenyl-6-aryl-1,2,4-
triazolo[3,4-b]-1’,3’,4’-thiadiazoles
2Synopsis.......
Substituted triazolo thiadiazoles of type-(I) have been prepared by the condensation of
3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with different aromatic acids in the
presence of phosphorous oxychloride.
PART-I I : STUDIES ON AMINOTHIADIAZOLES
Aminothiadiazole derivatives have attracted considerable attention in view of their great
therapeutic importance as antifungal, antibiotic, antihypertensive, and anticancer agents. To approach
these goal, preparation of some novel aminothiadiazoles have been undertaken as under.
SECTION-I : Synthesis and biological evaluation of  3-o-Chlorophenyl-6-arylamino-
1,2,4-triazolo[3,4-b]-1’,3’,4’-thiadiazoles
Aminothiadiazole derivative of type-(II) have been synthesized by the
condensation of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with different
aryl isothiocyanates in DMF.
N
N N
Cl
N
S
R
N
N N
Cl
N
S
NH R
Type-(I)           R=Aryl
Type-(II)           R=Aryl
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PART-III : STUDIES ON THIADIAZINES
Thiadiazines are incorporated with different therapeutic properties such as
analgesic, anthelmintic, anti-inflammatory etc. Considering these findings, it is thought
worthwile to synthesise some novel 1,3,4-thiadiazine derivatives to achieve potent agents,
described as under.
SECTION-I : Synthesis and biological evaluation of 5’-Aryl-5-o-chlorophenyl-
 [3,4-b]-1,2,4-triazolo[1’,3’,4’]-thiadiazines
The thiadiazine derivatives of type-(III) have been prepared by the condensation
of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with different substituted
phenacyl bromides.
PART-IV : STUDIES ON THIADIAZEPINES
Compounds containing thiadiazepine nucleus are found to possess diverse
pharmacological activities like antibacterial, antifungal, anti-HIV and anticancer agents.
Led by these considerations, it was of interest to synthesise some novel
thiadiazepine derivatives for better therapeutic potential.
SECTION-I : Synthesis and biological evaluation of 5-o-Chlorophenyl-1,2,4-
triazolo[3,4-b] substituted quinolino [2’,3’-f]-1",3",4"-thiadiazepines
N
N N
Cl N
S
R
Type-(III)       R=Aryl
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Thiadiazepine derivative of type-(IV) have been prepared by the condensation of
3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with substituted 2-chloro-3-
formyl-quinolines.
PART-V : STUDIES ON  MANNICH BASES
Mannich bases represent one of the modest class of compounds possessing wide range of
therapeutic activities, such as antimicrobial, antibiotic, antiviral. With a view to get better
therapeutic agent and to evaluate its pharmacological profile, different types of Mannich bases
have been prepared, which have been described as under.
SECTION-I : Synthesis and  biological evaluation of 4,N-Substituted benzalamino-
3-mercapto-5-o-chlorophenyl-1,2,4-triazoles
The azomethine derivatives of type-(V) have been prepared by the condensation of
3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with  different aryl aldehydes in
presence of con.H2SO4.
SECTION-I I: Synthesis and biological evaluation of  2-[Bis-aryl/alkyl-aminomethyl]-
5-o-chlorophenyl-4-substituted benzalamino-2,3-dihydro- [1,2,4]triazole-
3-thiones
N
N
N
N
S N
Cl X
Type-(IV)           X=Substituents
N
N N
Cl
N R
SH
Type-(V)       R=Aryl
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The preparation of Mannich bases of type-(VI) have been undertaken by the condensation
of compound of type-(V) with different secondary amines and formaldehyde.
PART-VI : STUDIES ON IMIDAZOLINONES
Oxo-imidazoline derivatives have been reported to be active as anticonvulsant, potent
CNS depressant, anti-inflammatory, sedative etc. In view of above findings, some novel oxo-
imidazoline derivatives have been synthesized, which have been described as under.
SECTION-I : Synthesis and biological evaluation of 1-3’-Mercapto--5’-o-chlorophenyl-
triazol-4’-yl-2-phenyl-4-arylidine-5-oxo-imidazoles
Imidazolinone derivatives of type-(VII) have been synthesized by the condensation
of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with substituted azlactones
which in turn, have been prepared by well-known Erlenmeyer azlactone synthesis.
N
N N
Cl
N R
S
N
R1
R2
Type-(VI)           R=Aryl,
   R1,R2=Alkyl/Aryl
N
N N
N
N
O
SH
R
Cl
Type-(VII)           R=Aryl
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[B] STUDIES ON  PYRIMIDINES
The efficiency of pyrimidine nucleus as pharmaceutical agent is well established and their
chemistry has been extensively studied. Pyrimidine moiety possess wide range of biological activities
such as anti-HIV, anticancer, calcium channel blockers, antitumor etc.
Taking these views into an account, synthesis of some novel oxo-pyrimidines, thio-
pyrimidines, S-alkyl pyrimidines and thiazolopyrimidines has been undertaken.
PART-I : STUDIES ON  PYRIMIDINES
The study of pyrimidines have revealed valuable drugs for the diseases like tuberculosis,
malaria, cancer, hypertention etc. Hence, it is pertinent to synthesize some novel pyrimidines,
described as under.
SECTION-I : Synthesis and biological evaluation of 4-Aryl-6-isopropyl-5-(3’-chloro,4’-
fluorophenyl aminocarbonyl )-1,2,3,4-tetrahydropyrimidin-2-ones
The synthesis of pyrimidine derivatives of type-(VIII) have been undertaken by condensation
of  N-3-chloro,4-fluorophenyl-3-(4-isopropyl)-3-oxopentanamide, urea and different aryl
aldehydes.
SECTION-II : Synthesis and biological evaluation of 4-Aryl-6-isopropyl-5-(3’-chloro,4’-
fluorophenyl aminocarbonyl )-1,2,3,4-tetrahydropyrimidin-2-thiones
NH
N
H
R
CH3
CH3
O
NH
O
Cl
F
Type-(VIII)           R=Aryl
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NH
N
H
R
CH3
CH3
S
NH
O
Cl
F
Type-(IX)           R=Aryl
The synthesis of pyrimidine derivatives of type-(IX) have been undertaken by condensation
of  N-3-chloro,4-fluorophenyl-3-(4-isopropyl)-3-oxopentanamide, thiourea and different aryl
aldehydes.
SECTION-III : Synthesis and biological evaluation of 4-Aryl-6-isopropyl-5-(3’-chloro,4’-
  fluorophenyl aminocarbonyl )-2-methylthio-3,4-dihydropyrimidines
The synthesis of pyrimidine derivatives of type-(X) have been undertaken by condensation
of   N-3-chloro,4-fluorophenyl-3-(4-isopropyl)-3-oxopentanamide, methyl imidothio carbamate
and different aryl  aldehydes.
N
N
H
R
CH3
CH3
S
NH
O
Cl
F
CH3
Type-(X)           R=Aryl
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PART-II : STUDIES ON  THIAZOLOPYRIMIDINES
Thiazolopyrimidines possess significant pharmacological importance and biological activities
such as antidepressant, antiviral, calcium channel blockers, anticancer etc. In view of the potential
biological activity of member of pyrimidine ring system, it was of interest to prepare some new
thiazolopyrimidines, which have been described as under.
SECTION-I : Synthesis and biological evaluation of 5-Aryl-7-isopropyl-6-(3’-chloro,4’-
fluorophenyl aminocarbonyl)-2,3-dihydro-thiazolo[2,3-b]pyrimidines
Thiazolopyrimidine derivatives of type-(XI) have been synthesized by the condensation of
4-aryl-6-isopropyl-5-3’-chloro,4’-fluorophenyl aminocarbonyl -1,2,3,4-tetrahydropyrimidin-2-
thiones, 1,2-dibromoethane in DMF.
[C] STUDIES ON MICROWAVE  ASSISTED SYNTHESIS OF 5,6-
DIHYDRO-1,3,4-THIADIAZOLOTRIAZOLES
In the recent year, MORE (Microwave Induced Organic Reaction Enhancement) technique
has become very popular due to substantial reduction in reaction time, operational time,operational
simplicity and formation of clearer reaction products. Keeping this in view, we investigated the
synthesis of dihydrothiadiazoles using microwave irradiation and also by conventional method.
N
N
R
CH3
CH3
S
NH
O
Cl
F
Type-(XI)           R=Aryl
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PART-I : STUDIES ON 5,6- DIHYDRO-1,3,4-THIADIAZOLOTRIAZOLES BY
               CONVENTIONAL AND MICROWAVE INDUCED SYNTHESIS
Dihydrothiadiazole derivatives have been found to be potent drugs in pharmaceuticals and
possessing a wide range of biological activities such as anticancer, antifungal, antiviral etc.
In view of these findings, it appeared of interest to design and synthesise thiadiazole
derivatives which have been described as under.
SECTION-I : Synthesis and biological evaluation of  3-o-Chlorophenyl-5,6 dihydro-6- aryl-
1,2,4-triazolo[4,5-b]-1,3,4-thiadiazoles by conventional method
The compounds of type-(XII) have been prepared by the condensation of
3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with different aromatic aldehydes in
presence of p-tolylsulphonic acid.
SECTION-II : Synthesis and biological evaluation of  3-o-Chlorophenyl-5,6 dihydro-6- aryl-
1,2,4-triazolo[4,5-b]-1,3,4-thiadiazoles by microwave method
N
N N
Cl
N
H
S
R
Type-(XII)           R=Aryl
N
N N
Cl
N
H
S
R
Type-(XII)           R=Aryl
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The compounds of type-(XII) have been prepared by the condensation of
3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with different aromatic aldehydes in
presence of p-tolylsulphonic acid under microwave irradiation in few minutes.The
advantages of microwave synthesis has been reported.
CHARACTERISATION :
The constitution of newly synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
In vitro study on multiple biological activities
(i) All the compounds have been evaluated for their antibacterial activity towards Gram positive
and Gram negative bacterial strains and antifungal activity towards Aspergillus niger at a
concentration of 40  ì g. The biological activity of the synthesised compounds have been
compared with standard drugs.
(ii) Selected compounds have been evaluated for their in vitro biological assay like antitubercular
activity towards a strain Mycobacterium tuberculosis H37RV  at a concentration of
6.25  ì g/ml using Rifampin as a standard drug, which have been tested by Tuberculosis
Antimicrobial Acquisition Coordinating Facility (TAACF), Alabama, U.S.A.
Signature of Guide                  Signature of candidate
       Dr. (Mrs.)H. H. Parekh                   (Bhavin S. Shukla)
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“STUDIES ON CHEMICAL ENTITIES OF PHARMACEUTICAL INTEREST”
Research in the field of pharmaceutical has its most important task in the
development of new and better drugs and their successful introduction into clinical
practice. Central to these efforts, accordingly stand the search for pharmaceutical
substances and preparation which are new and original. In addition to these objectives,
we may search for newer drug like entities which exhibit some clear advantages over a
drug already known. Such advantages may be qualitative or quantitative improvement in
activity, the absence of undesirable side effects, lower toxicity, improved stability or
decreased cost.
A prerequisite for the design of safe drug is, knowledge about the various
metabolic reactions that xenobiotics and endogenous compounds undergo in the organism.
Because pharmacological activity associated with molecular structure, medicinal chemist
is restricted in the choice of functional groups for the design of new drugs. Often he
finds or she encounters a situation where a structure has  adequate pharmacologic activity
but has an inadequate pharmacokinetic profile (i.e., absorption, distribution, metabolism
and excretion). This is because pharmacology and pharmacokinetic departments in the
pharmaceutical industry often do not collaborate at the early stage of drug development.
It is only later, when the new compound is tested in animals or in humans, that pharmaco-
kinetic disadvantages  become obvious.
Drug action is believed to be due to the interaction of the drug with enzymes,
receptors and other molecules found in the biological system. The binding of a drug to the
active or other sites of an enzyme usually has the effect of preventing the normal operation
of that enzyme. The drug’s therapeutic effect will depend on the stability of the drug-
enzyme complex as well as the fraction of active and allosteric sites occupied by the
drug. The stronger the binding of the drug to the enzyme and greater the number of sites
occupied, the more effective the drug is likely to be in inhibiting the action of the enzyme.
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The degree of drug activity is directly related to the concentration of the drug in
the aqueous medium in contact with the active or receptor site. The factors affecting this
concentration in a biological system can be classified in to two phase.
(I) The pharmacokinetic phase
It is concerned with the study of the parameters that control the journey of the
drug from its point of administration to its point of action. It includes the absorption,
distribution, metabolism and elimination of a drug.
(II) The pharmacodynamic phase
It is concerned with the result of the interaction of drug and body at the receptor
site, that is, what the drug does to the body. This includes physiological and
biochemical effects of drugs and their mechanism of action at macromolecular/sub
cellular organ systems.
Heterocyclic chemistry and medicinal chemistry share a venerable common
history. Many of the founders of heterocyclic systems had an intense interest not only in
molecules from nature but also in the effects of synthetic compounds on living
systems.There are two main divisions of medicinal chemistry. The first chemotherapy,
concerns the treatment of infections, parasite or melignant disease by chemical agents,
usually substances that show selective toxicity towards the pathogen. The other division
relates to diseases of bodily disfunction and the agents employed are mainly compounds
that effect the functioning of enzymes, the transmission of impluses or the action of hormones
on receptors.
Heterocyclic compounds have great applicability in pharmaceutics because they
have specific chemical reactivity and provides false synthons in biosynthetic process or
block the normal functioning of biological receptors. The inhibition of amide resonance
resulting into more susceptibility of  β-lactam to nucleophile is considered at least in
part responsible for antibacterial property, apparently by acetylating transpeptidase and
thus inhibiting bacterial cell wall biosynthesis.
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Heterocyclic compounds are used because they have a specific clinical
reactivity.With the number of  known organic compounds approaching five million, more
than half of which are heterocyclic and out of these more than half of heterocyclic
system attach with another ring system and give pharmacological activity.
Most of the alkaloids which are nitrogenous bases occurring in plants and many
antibiotics including penicillin and streptomycin have also heterocyclic ring system. Many
natural pigments such as indigo, haemoglobin and anthocyanin are heterocycles. Most
of the sugars are their derivatives including Vitamin-C for instance, exist largely in the
form of five membered. Vitamin B-6 (Pyridoxine) is a derivative of pyrimidine essential
in amino acid metabolism.
The current interest in the creation of large, searchable libraries of organic
compounds has captured an imigination of organic chemist and the drug discovery
community. Efforts in numerous laboratories focused on the introduction of chemical
diversity have been recently reviewed and pharmacologically intresting compounds have
been identified from libraries of widely different composition.
Our goal for this is to begin to deconvolute this information in order to apply it to
design of new drugs.
AIMS AND OBJECTIVES
Taking in view of the applicability of heterocyclic compounds, we have under-
taken the preparation of heterocycles bearing triazole and pyrimidine nucleus. The place-
ment of a wide variety of substituents of these nuclei have been designed in order to
evaluate the     synthesized products for their pharmacological profile against several
strains of bacteria and fungi.
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During the course of our research work, looking to the application of hetero-
cyclic compounds, several entities have been designed, generated and characterized
using spectral studies. The details are as under.
♦ To generate several derivatives like 1,3,4-thiadiazolo triazoles, 1,3,4-amino-
thiadiazolo triazoles, 1,3,4-thiadiazines, 1,3,4-thiadiazepines, azomethines,
mannich bases and imidazolinones bearing 1,2,4-triazole nucleus.
♦ To synthesise biologically active 5,6-dihydro-1,3,4-thiadiazolotriazoles
bearing 1,2,4-triazole nucleus using microwave induced synthesis method.
♦ To genrate different substituted oxopyrimidines, thiopyrimidines, s-methyl
pyrimidines and thiazolopyrimidines by using MCR (Multi Component Reaction)
concepts.
♦ To check purity of all the compounds using thin layer chromatography.
♦ To characterise these products for stucture elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
♦ To evaluate new products for better drug potential against different strains
of bacteria, fungi and for antitubercular activity against Mycobacterium
Tuberculosis H37Rv.
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INTRODUCTION
 Triazoles, which belong to an important group of heterocyclic compounds have
been extensively explored for their applications in the field of medicine. Triazole bears
three nitrogen atoms in five-membered ring system. Triazoles are of two types 1,2,3
triazole (I) and 1,2,4-triazole (II).
The first 1,2,4-triazole derivative was synthesised by Bladin1,2 in 1885. Recently,
much attention has been focused on 1,2,4-triazole derivatives for their broad spectrum
of activities.1,2,4-Triazole derivatives are not only known for their medicinal applications
but also used as an analytical reagents3, photographic chemicals4 and in polymer5
synthesis.
SYNTHETIC ASPECTS
Practically, all synthesizing methods for triazole starts with thiosemicarbazide or,
dithiocarbamate derivatives possessing nitrogen containing function, that is the starting
material. Different methods for the preparation of triazole derivatives are as under.
1. Reid and Heindel6 reported that the reaction of aryl acidhydrazide with
CS2/KOH and hydrazine hydrate furnished triazoles.
ν-Triazole or 1,2,3-Triazole  (I)
(III)
N
H
N
N
N
NH
N
N
H
N
N
N
N
H
N
N
N
NH
s-Triazole or 1,2,4-Triazole   (II)
R
O
NH
NH2
CS2
KOH
R
O
NH
NH
S
S K
- + NH2.NH2.H2O
N
N N
NH2
R SH
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2. Reaction of aroyl-cyanide (α-oxonitriles) with phenyl hydrazine yields 3-amino-
5-aryl-2-phenyl-2H-1,2,4-triazole as reported by B. J. Rai and co-workers7.
3. Shin-Ichi Nagai8 synthesised triazoles by the reaction of thiosemicarbazide
with formic acid in presence of acetic anhydride.
4. Ahamad S. Shawali et al.9 synthesised 1,2-bis (4-amino-5-mercapto-4H-
1,2,4-triazol-3-yl) ethane by heating succinic acid with two molar equivalents
of carbonothioic dihydrazide in an oil bath at 170oC.
5. C. S. Andotra and Sukhbinder Kaur10 synthesised triazolopyrimidine by
the reaction of aromatic acid with substituted hydrazino pyrimidine.
6. Kap-Sun Yeung et al.11 synthesised 3,5-disubstituted 1,2,4-triazoles from
nitriles and hydrazides in presence of basic catalyst.
HOOC
COOH
+
NH2
NH NH
NH2
S
-4H2O
N
N
N
H
N
H
N
N
NH2
S
S
NH2
2
(IV)
-C6H5NH2
O
N
+ 2.C6H5NH.NH2
N
N
N
C6H5
NH2
X
X
N
N
NH
NH2
R
R1
N
N
N
N
R
R1
R2
R2
O
OH
(VI)
(V)
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THERAPEUTIC IMPORTANCE
1,2,4-Triazole derivatives have been reported to be associated with diverse
biological activities. Drug molecules having 1,2,4-triazole nucleus with good activity
are listed as under..
NN
N
O
OH
OHOH
NH2 NH2
+
Fungicide
N
N
N
N
NH2
O
CH3
N
N N
CH3 CH3NC
CH3
CH3
NC
Bemitradine
Diuretic
Anastrozole
 Antineoplastic,
 Aromatase Inhibitor
R1 C N +
R2
O
NH
NH2
N
N NH
R1 R2
K2CO3, n-BuOH
150 C
(VII)
Viramidine
N
N
N
O
Cl
Cl
N CH3
CH3
O
Rilmazafone
Sedative, Hypnotic
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N
N
N
O P S
O
O
CH3
CH3
Triazophose
Pesticide
N
N
N
O
O
CH3
N N
Cl
Antifungal
N
NN
OH
CH3
CH3
CH3
Cl
Paclobutrazole
Plant  growth  regulator
Nefazodone
Alprazolam
Anticonvulsant
N
N
N
N
CH3
Cl
N
N
N OH
CH3
CH3
CH3
O
Bitertanol
Agriculture fungicide
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According to literature survey various 1,2,4-triazole derivatives have resulted in
many potential drugs and are known to exhibit a broad spectrum of biological activities.
Therapeutic activity of 1,2,4-triazoles are listed as under.
1. Diuretic12
2. Antiviral13
3. Antihypertensive14
4. Antiarthritic15
5. Anticonvulsant16
6. Anthelmintics17
7. Herbicidal18
8. Anticancer19
9. Bactericidal20
10. Antimicrobial21
11. Fungicidal22
12. Insecticidal & Acaricidal23
13. Plant growth regulator24
14. Antileishmanial25
15. Antidepressant & Anxiolytic26
16. Antitumor27
17. Antiinflammatory28,29
Andreina Liendo et al.30 have discovered both enantiomers of 2-(2,4-
difluorophenyl)-1-[3-(z)-4-(2,2,3,3-tetrafluoropropoxy)styryl]-1,2,3-triazole-1-yl)-3-
propane-2-ol. It has recently been shown that the R(+) enatiomer of bis triazole
derivatives (VIII) can induce radical parasitological cure in marine mouldes of the acute
and chronic forms of the disease.
N
N
N
N
N
N
O
CF2 CHF2
(VIII)
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Daniele Bianchi et al.31 have screened pure stereoisomer of two new triazole
derivatives (IX,X) for their antifungal activity against variety of  fungi showing an activity
ratio R-form/S-form upto 400.
A series of new 1H-1,2,4-triazole derivatives were synthesised and evaluated in
vitro for activity against various DNA and RNA viruses by E. De Clercq et. al.32 Various
4-N-substituted amino-4H-1,2,4-triazole derivatives were synthesized and evaluated
for aromatase-inhibitory activity (in vitro) and for pregnant mare serum gonadotropin
(PMSG)-induced estrogen synthesis-inhibitory activity by Fujikura T. and co-workers33.
Bignon Eric et. al.34 have reported    N-triazolyl-2-indole carboxamides and their use
as CCK-A agonists. These compounds have partial or total CCK-A receptor agonist
activity and are useful for treating eating problem, obesity, tardive dyskinesia and
disorders of the gastrointestinal sphere (XI).Sun-Qingyan et al.35 have synthesised
triazole (XII) and reported their antifungal activity.
Mevlut Ertan and co-workers36 have synthesised 6-benzylidenethiazolo[3,2-b]-
1,2,4-triazole-5(6H)-ones and evaluated for their antiinflammatory activity. In gastric
ulceration studies the synthesized compounds were generally found to be safe at a 200
mg/kg dose level.
OH
N
N
N
Cl
Cl
OCF2CHF2
N
N
N
Cl
Cl (X)(IX)
N
N N
NH C
O N
R'
R
R'
(XI)
N
N
N
R
OH
F
F
(XII)
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Dawei Cui et al.37 have prepared some new triazoles (XIII) and reported them
as significant antifungal agent. Liu Chanjian et al.38 have investigated triazoles (XIV) as
IMPDH inhibitors.
B. Shivarama Holla et al.39 have investigated some triazole derivatives as
anticancer agent. Balkovec et. al.40 have formulated triazoles as antidiabetic agent.
Neslihan Demirbas and co-workers41 have documented antimicrobial activity of some
newly synthesised 1,2,4-triazole derivatives. L. Labanauskas et. al.42 have documented
antiinflammatory activity of some triazoles. Yaseen A. et. al.43 have prepared 1,5-dialkyl-
3-(5-mercapto-4,N-aryl-1H-1,2,4-triazol-3-yl-methylene)-1H-1,2,4-triazoles which
exhibited remarkable activity against nine types of cancer and also antiviral activity.
M.Dincer et al.44 have synthesised triazole derivatives (XV) as potential antimicrobial
agent. L.H.Mackendry and co-workers45 have investigated triazole derivatives (XVI)
and reported them as broad spectrum broadleaf herbicides.
Recently, Neslihan Demirbas et. al.46 have screened triazole derivatives for their
antiinflammatory, anticancer, antitubercular and antihypertensive acitivities. Nawal A.El-
Koussi et. al.47 have prepared a series of 5-phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-
3-carboxylic acid derivatives. Some of the compounds were found to be equipotent or
N
NN
NH S
S
CH3
NH
R1 R2
R3
(XIV)
N
N
N
N
NH
NH2
O
N
OCH3
(XIII)
N N
N
NH
Cl Cl
CH3
N
N N
N
EtO
FSO2
NH
ClCl
(XVI)(XV)
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more potent than Indomethacin and Celecoxib as reference drugs at two dose levels, 5
and 10 mg/kg, and they have no ulcerogenic activity. Marie-Odile Contour-Galcera et. al.48
have synthesised 3-thio-1,2,4-triazoles(XVII) and reported as non-peptidic human
somatostatin receptor subtypes 2 and 5 agonists. K.M.Basavaraja and co-workers49
have prepared triazole derivatives(XVIII) and reported their antibacterial activity.
Thus, interesting biological activities of a novel heterocycle like triazole have
stimulated considerable research work in recent years leading to the synthetic utility of
the derivatives of this ring system.These valid observations led us to synthesise several
derivatives like 1,3,4-thiadiazoles,1,3,4-thiadiazepines, 1,3,4-thiadiazines,
5-imidazolinones, Mannich bases and dihydrothiadiazoles bearing 1,2,4-triazole nucleus
in order to achieving better therapeutic agents which have been described as under.
[A] STUDIES ON TRIAZOLES
PART-I    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZOLOTRIAZOLES
PART-II  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
AMINOTHIADIAZOLE DERIVATIVES
PART-III  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZINES
N N
N
O O
R
R'
N
NN
S
R3
R1
R2
(XVII) (XVIII)
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PART-IV  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZEPINES
PART-V  : SYNTHESIS AND BIOLOGICAL EVALUATION OF
MANNICH BASES
PART-VI  : SYNTHESIS AND BIOLOGICAL EVALUATION OF
IMIDAZOLINONES
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INTRODUCTION
 Thiadiazole ring has attracted attention world wide, having one sulphur and two
nitrogen atoms. This ring system with three hetero atoms does not exhibit tautomerism in
its fully conjugated form. However, when certain substituents are present tautomerism is
possible. It is documented in the literature that this five membered ring system contains
the following members : The 1,2,3-thiadiazoles(I), 1,2,4-thiadiazoles(II), 1,3,4-
thiadiazoles(III) and 1,2,5-thiadiazoles(IV) and their benzo derivatives. Amongst these,
1,3,4-thiadiazole derivatives have been found to be potent drugs in pharmaceutical
industries and exhibited various biological activities due to the presence of the -N=C-S
group50.
1,3,4-Thiadiazoles were first described in 1882 by Fischer. Further development
was done by Busch and co-workers. The advent of sulfur drugs and their discovery of
mesoionic compounds greatly accelerated the rate of progress in the field of thiadiazoles.
The literature of 1,3,4-thiadiazoles have been extensively reviewed as under.
Sandstrom51 (1947), Sherman52 (1951), Bambas53 (1952), F. Kurzer54
(1977), M. Davis55 (1979) and Campbell56 (1979).
SYNTHETIC ASPECTS
Several publications and patents described the synthesis of 1,3,4-thiadiazoles as
under.
1. Li-Xue Zhang et al.57 have synthesized 1,3,4-thiadiazoles by the cyclization of
aromatic acid with triazole in the presence of POCl3.
S
N
N
S
N
N
S
N N
S
N N
(I) (II) (III) (IV)
 1
 2
 3
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2. Jag Mohan et al.58 have prepared thiadaizole derivative from amino-mercapto
triazole in the presence of  p-Ts-OH.
3. Microwave irradiation used for the preparation of thiadiazole using DMF as an
energy transfer medium by Kidwai Mazaahir et al.59
4. Ahmad M. Farag et al.60 have proposed one step synthesis of thiadiazole
derivative N-N’-diaryl-oxalodihydrazonyl dihalides reacts with potassium
thiocyanate yield the thiadiazole derivatives.
5. Z. Kaleta et al.61 have prepared novel thiadiazole derivatives by the use of
fluorous Lawesson’s reagent.
Ar-CHO
p-Ts-OH
N
N
N
N
S
R
R1
NN
N
R
NH2
SH
NH N
X N
X
NH
Ar
Ar
KCNS N
S
N
S
N
N
NH
Ar
NH
Ar
NHR
O
NH R
O P P
S
S
SS
ArAr
1 eq. F. Lawesson's
 17 hrs.
Reagent, THF, 55 C. 
S
NN
Ar R
N N
N
NH2
O
SH
POCl3
Ar-COOH
N N
N
O
S
Ar(V)
(VI)
(VII)
(VIII)
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THERAPEUTIC IMPORTANCE
Extensive research has been carried out to enhance the activity of thiadiazole
drugs. Thiadiazole derivatives have resulted in many potential drugs and are known to
exhibit numerous pharmacological activities described as under.
1. Antiviral62
2. Amoebicidal63
3. CNS depressant64
4. Antagonist agent65
5. Antiinflammatory66
6. Insecticidal67
7. Antimicrobial68-70
8. Antitumor71
9. Antipyretic72
10. Antitubercular73
11. Algaecides and antifouling74
12. Antihypertensive75
13. Anthelmintic76
Andanappa K Gadad et al.77 have prepared thiadiazoles and reported them as
antibacterial agents. Clerici F.et al.78 have synthesised and screened 1,3,4 thiadiazoles
for their antidepressant and anxiolytic activity. The purpose of this study was to evaluate
the effect of the compounds on CNS activity by varying the substituents  in the thiadiazole
moiety. It was found that some compounds possess marked antidepressant and anxiolytic
activity comparable in efficiency to the reference drug imipramine. Erhan Palaska
et al.79 investigated some thiadiazoles possessing anti-inflammatory activity. Bernard
Masercel et al.80 have discovered some novel thiadiazoles possessing potent carbonic
anhydrase inhibitor properties and also prepared  5-valproylamido 1,3,4-thiadiazole-2-
sulfonamide (IX), useful as strong anticonvulsant.
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Samir A. Carvalho et al.81 have synthesized series of thiadiazole derivatives from
which compound (X) was identified as a new potent trypanomicide, that is brazilizone
(A).
Hatice N. Dogan et al.82  have reported thiadiazole derivatives (XI-a,b), the
degree of protection afforded by these compounds against PT2-induced convulsions in
mice ranged from 0-90%. The compound shows both anticonvulsant and antimicrobial
activity against Gram positive and Gram negative organism.
Lisa M. Thomasco et al.83 have reported that replacement of morpholine ring
with 1,3,4-thiadiazolyl ring (XII) leads to better antibacterial activity. Andanappa K.
Gadad et al.84 have synthesised  compounds of the type (XIII), and the selected
compounds were evaluated for their preliminary  in vitro antitubercular activity against
Mycobacterium Tuberculosis H37Rv strain using radiometric BACTEC and  broth
dilution assay method and most of the compounds exhibited moderate to good activity.
CONHMe
N
H
S
N
H2NO2S
(IX)
N
N
S
N N
NH
N
OH
OH
CH3
CH3
(X)
S
N N
NH
R
OH
S
N N
R
OCOCH3
COCH3
(XI-b)(XI-a)
S
N N
N
O
R
F
O
CH3COHN
(XII)
N
S
N
N R3
R2
R1
R1 = SO2NH2, CH3 R2 = Br, SCN
R3 = Aryl / Heterocycles
(XIII)
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Kwan-Young Jung and co-workers 85 have developed potent and selective human
adenosine A3 receptor antagonists. From all the compounds the most potent A3 receptor
antagonists is 4-methoxyphenyl derivative. Jui-Yi-Chou et al.86 have synthesized  several
thiadiazole derivatives and examined their cytotoxic effect on human non-small cell lung
cancer A549 cells and found that thiadiazole derivatives are the most effective one by
the MMT assay.
Ishvarsinh Rathod  and co-workers87 have synthesized N-(1,3,4-thiadiazolo-2-
yl)-5-(substituted)-2-amino-4,5-(disubstituted) thiophene-3-carboxylic acids (XIV) as
analgesics and  antiinflammatory agents. Gundurao Kolavi et al.88 have prepared new
imidathiadiazole derivatives (XV), which act as powerful antitubercular agents with 100%
inhibitory activity (MIC > 6.25 mg/ml).
CONTRIBUTION FROM OUR LABORATORY
H. H. Parekh et al.89 have formulated some new thiadiazoles as biologically
active agents. Parikh et. al. have used substituted thiazolidinone90, 4-pyridyl91 moieties
at 5-position (Y) in 1,3,4-thiadiazole ring system and at 2-position (X) was substituted
by aryl amino and s-triazine92. H. H. Parekh and co-workers have synthesised 1,3,4-
thiadiazoles having dapsone93,94 bis moiety at 5-position (Y) and benzalamino,
benzoylamino and sulphonamido, aryl95  moiety substituted at 2-position (X). General
structure for above references are as under.
(XIV)
S
NH S
N N
CH3
R1
R2
R
O
N
S
N
N
CHO
(XV)
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 Mohd Amir and Kumar Shikha96 have prepared 1,3,4-thiadiazoles which exhibit
antiinflammatory, analgesic as well as ulcerogenic activity. Amir M.et al97 have
synthesised thirteen cyclised derivatives of thiadiazole ring system. Out of  them, eleven
screened for their anti-inflammatory activity by Winter et al. method and four compounds
showed significant activity. These compounds also inhibit lipid peroxydation in the gastric
mucosa and showed gastrosparing activity. Joanna Matysiak and co-workers98 have
discovered the new thiadiazole derivatives which shows antiproliferative activity. From
the series of the compounds, 2-(2,4,-dihydroxyphenyl)-5-(4-methoxybenzyloxy)1,3,4-
thiadiazole, exhibits highest antiproliferative activity against human cancer cell lines. Oruc
E.E   et al.99 have synthesized thiadiazoles and studied their analgesic activity.
In view of the pronounced biological activities of 1,3,4-thiadiazoles, the synthesis
of new derivatives which contain above mentioned pharmacologically active nuclei have
been undertaken.
SECTION-I :SYNTHESIS AND BIOLOGICAL EVALUATION OF  3-o-
CHLOROPHENYL -6-ARYL-1,2,4-TRIAZOLO[3,4-b]-1,3,4-
THIADIAZOLES
S
N N
X Y
CH2 IPr
CH3
CH3
H
NH C O HC N
, , , ,X =
N
SO
R
CH3
N
S
CH3
N
NN
NH NH
O O
NH
R
NH
R
S
CH3
CONH
Y = , , ,
(XVI)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-o-CHLOROPHENYL -6-
ARYL-1,2,4-TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLES
The study of 1,3,4-thiadiazoles have revealed that thiadiazole derivatives are
valuable drugs for various diseases. These valid observations led us to synthesise
thiadiazole derivatives of type-(I) by the cyclization of 3-mercapto-4,N-amino-5-o-
chlorophenyl-1,2,4-triazole with different aromatic acids in the presence of phosphorous
oxychloride.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesized compounds were compared with standard drugs.
The synthesized compounds have been screened for their in vitro biological
assay  l ike  an t i tubercu la r  ac t iv i ty  towards  a  s t r a in  o f  Mycobac ter ium
tuberculosisH37Rv at a concentration of 6.25 µg/ml using Rifampin as standard drug.
N N
N
N
S
R
Cl
        Type - (I)          R=Aryl
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REACTION SCHEME
        Type - (I)                   R=Aryl
N N
N
NH2
SH
Cl
O
NH NH2
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
N N
N
N
S
R
Cl
R-COOH
POCl3
COOH
Cl
COOC2H5
Cl
C2H5OH
Con.H2SO4
NH2.NH2.H2O
CH3OH
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2922 2975-2950 420
-CH3 C-H str. (sym.) 2852 2880-2860  “
C-H i.p.def. (asym.) 1498 1470-1435  “
C-H o.o.p. def. (sym.) 1372 1390-1370  “
Aromatic C-H  str. 3052 3080-3030 421
C=C str. 1541 1585-1480  “
C-H i.p. def. 1059 1125-1090  “
C-H o.o.p. def   836  835-810  “
Triazole C=N str. 1605 1612-1593 420
moiety C-N str. 1306 1350-1200 423
N-N str. 1025 1050-1010 420
C-Cl str.   757  600-800 422
Ether C-O-C str. (asym.) 1255 1275-1200 420
C-O-C str. (sym.) 1025 1075-1020  “
                                               (overlapped)
Thiadiazole C-S-C str. 684                      720-570 424
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDY OF 3-o-CHLOROPHENYL-6-(p-METHOXYPHENYL)-
1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
20.0
40.0
60.0
80.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 427.2
 463.8
 573.8
 599.8
 684.7
 757.0
 836.1
1025.1
1059.8
1179.4
1234.4
1255.6
1306.7
1372.3
1467.7
1498.6
1541.0
1605.6
2852.5
2922.9
3052.1
N N
N
N
S
O CH3
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 3-o-CHLOROPHENYL-6-p-BROMOPHENYL-1,2,4-
TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 7.50-7.46 1H double Ar-Ha      -
triplet
2. 7.56-7.51 1H multiplet Ar-Hb      -
3. 7.63-7.61 1H doublet Ar-Hd   Jdc=9.2
4. 7.70-7.68 2H double Ar-Hee’   Jef=8.4
doublet
5. 7.79-7.74 2H double Ar-Hff’   Jfe=8.4
doublet
    6. 7.86-7.81 1H multiplet Ar-Hc      -
N N
N
N
S
Cl
Br
a
b
c
e
e'
d
f
f'
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MASS SPECTRUM
EXPANDED AROMATIC REGION
N N
N
N
S
Cl
O CH3
N N
N
N
S
Cl
Br
a
b
c
e
e'
d
f
f'
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF  3-o-CHLOROPHENYL -6-
ARYL-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
(A) Synthesis of Ethyl-o-chlorobenzoate100,101
A mixture of 2-chlorobenzoic acid (1.56 g, 0.01M) in ethanol (20 ml) and con.
H2SO4 (1 ml) was refluxed for 18 hrs. The reaction mixture was poured into ice cold
water. The product was then isolated. Yield 87%, b.p. 242oC.
(B) Synthesis of o-Chlorobenzoic acidhydrazide100,101
A mixture of ethyl-2-chlorobenzoate (1.84 g, 0.01M) in ethanol (20 ml) and
hydrazine hydrate (0.5 g, 0.01M) was refluxed for 5-6 hrs. The reaction mixture was
poured into ice cold water. The product was isolated and crystallised from ethanol.
Yield 84%, m.p. 118oC.
(C) Synthesis of Potassium -o-chlorobenzoyl dithiocarbamate100,101
A mixture of potassium hydroxide (0.84 g, 0.015M) in absolute ethanol
(25 ml), o-chlorobenzoic acidhydrazide (1.70 g, 0.01M) and carbon disulfide (1.14ml,
0.015M) was stirred for 24 hrs. The product was precipitated by adding diethyl ether
(150 ml). Yield 94%.
(D) Synthesis of 3-Mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole
A suspension of potassium o-chlorobenzoyl dithiocarbamate (2.91 g, 0.01M),
hydrazine hydrate (95%, 1ml, 0.02M) and water (1 ml) was refluxed with stirring for
8 hrs. The content was diluted with water and acidified with glacial acetic acid to isolate
the product. It was crystallized from ethanol. Yield 58%, m.p. 185oC, (C8H7ClN4S :
required : C, 42.39; H, 3.11; N, 24.72; found : C, 42.53;  H, 3.27; N, 24.94%).
TLC solvent system : Ethyl acetate : Hexane (4 : 6).
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(F) Synthesis of  3-o-Chlorophenyl -6-(p-methoxyphenyl)-1,2,4-triazolo[4,5-b]-
1,3,4-thiadiazole
A mixture of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole (2.26 g,
0.01M) and p-methoxybenzoicacid (1.52 g, 0.01M) in phosphorous oxychloride
(20 ml) was refluxed for 12 hrs. It was cooled and poured onto crushed ice and
neutralized with sodium bicarbonate. The product was isolated and crystallized from
ethanol. Yield 72%, m.p. 156oC (C16H11ClN4OS ; required : C, 56.06; H, 3.23;
N, 16.34, found : C, 56.27; H, 3.39; N, 16.49%).
TLC solvent system :  Ethyl acetate : Hexane (4 : 6).
Similarly other substituted 1,3,4-thiadiazolo triazole derivatives were
synthesized. The physical datas are recorded in Table No.1.
(G) Antimicrobial activity of  3-o-chlorophenyl -6-aryl-1,2,4-triazolo[4,5-b]-
1,3,4-thiadiazoles
All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity
Antimicrobial activity was carried out by cup-plate agar diffusion method52 which
has been described as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The nutrient
agar broth prepared by the usual method, was inoculated aseptically with 0.5 ml of
24 hrs. old subcultures of B. coccus, S. aureus, E.aerogenes, P. aeruginosa in separate
conical flasks at 40-50oC and mixed well by gentle shaking. About 25ml content of the
flask were poured and evenly spreaded in a petridish (13cm in diameter) and allowed to
set for 2 hrs. The cups (10 mm in diameter) were formed by the help of borer in agar
medium and filled with 0.04ml (40µg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also maintained
with 0.04 ml of DMF in a similar manner and the zones of inhibition of the bacterial
growth were measured in millimeter and are recorded in Graphical Chart No.1.
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The antibacterial activity data of the synthesised compounds have been
compared with standard antibiotics like amoxicillin, benzoyl penicillin, ciprofloxacin and
erythromycin.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on Sabouraud’s agar slants. Sterilized Sabouraud’s agar
medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal spores in a separate
flask. About 25 ml of the inoculated medium was evenly spreaded in a petridish and
allowed to set for two hrs. The cups (10 mm in diameter) were punched and filled with
0.04 ml (40 µg) solution of sample in DMF. The plates were incubated at 30oC for 48
hrs. After the completion of incubation period, the zones of inhibition of growth in
the form of  diameter in mm was measured. Along the test solution in each petridish one
cup was filled with solvent which acts as control. The zones of inhibition were compared
with standard antifungal Greseofulvin. The zones of inhibition are recorded in Graphical
Chart No. 1.
(b) Antitubercular activity
The antitubercular evaluation of the compounds was carried out at Tuberculosis
Antimicrobial Acquisition and Co-ordination Facility (TAACF), U.S.A. Primary screening
of the compounds for the antitubercular activity have been conducted at 6.25 mg/ml
towards Mycobacterium tuberculosis H37Rv in BACTEC 12B using the BACTEC
460 radiometric system. The compounds demonstrating atleast >90% inhibition in the
primary screening has been tested at lower concentration towards Mycobacterium
tuberculosis H37Rv to determine the actual minimum inhibitory concentration (MIC)
in the BACTEC-460.
The antitubercular activity data have been compared with standard drug Rifampin
at 0.25 µg/ml concentration and it showed 98% inhibition.
39Thiadiazoles......
ANTIMICROBIAL ACTIVITY
Method : Cup-Plate102
Gram positive bacteria : Bacillus coccus
Staphylococcus aureus
Gram negative bacteria : Enterobacter aerogenes
Pseudomonas aeruginosa
Fungi : Aspergillus niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzoyl penicillin,
Ciprofloxacin, Erythromycin
Greseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin,
Benzoyl penicillin, Ciprofloxacin, Erythromycin and antifungal activity was compared
with viz Greseofulvin. The inhibition zones are measured in mm.
       ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at Tuberculosis
Antimicrobial Acquisition Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium Tuberculosis H37Rv
Concentration : : 6.25 µg/ml.
Standard drug: : Rifampin.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antimicrobial activity of thiadiazoles type-(1) revealed that all the compounds
were able to inhibit the growth of Gram positive and Gram negative bacterial strains.
From the exeperimental data it has been observed that the compound bearing
R= 4-methoxyphenyl and 2,4-dihydroxyphenyl have displayed considerable activity
21mm, 20mm against S. aureus.
In case of Gram negative bacterial strain, maximum activity was observed in
compounds bearing R=2,4-dihydroxyphenyl have fairly inhibited 21mm the growth of
E.aerogenes. While in case of  P.aeruginosa. compound bearing R=2-bromophenyl
and pyridyl have displayed significant activity 20mm, 21mm.
ANTIFUNGAL ACTIVITY
All the compounds are found to be active against A. niger. Maximum activity
was shown by the compounds bearing R=2-bromophenyl (23mm) .
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & greseofulvin.
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TABLE NO. 1a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
295762 SB-10 2,4-(OH)2-C6H3- Alamar H37Rv >6.25 0 - MIC Rifampin =
  0.25 mg/ml
@ 98% Inhibition
295760 SB-08 2-Cl-C6H4- Alamar H37Rv >6.25 08 - "
295756 SB-04 4-NO2-C6H4- Alamar H37Rv >6.25 11 - "
295755 SB-03 4-Br-C6H4- Alamar H37Rv >6.25 13 - "
295754 SB-02 4-CH3-C6H4- Alamar H37Rv >6.25 13 - "
295759 SB-07 2-CH3-C6H4- Alamar H37Rv >6.25 14 - "
295753 SB-01 4-OCH3-C6H4- Alamar H37Rv >6.25 17 - "
295763 SB-11 2,4-(Cl)2-C6H3- Alamar H37Rv >6.25 21 - "
295757 SB-05 4-NH2-C6H4- Alamar H37Rv >6.25 36 - "
295764 SB-12 C5H4N- Alamar H37Rv >6.25 36 - "
   295758 SB-06 4-OH-C6H4- Alamar H37Rv >6.25 40 -  "
295761 SB-09 2-NH2-C6H4- Alamar H37Rv >6.25 83 - "
N N
N
N
S
R
Cl
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID Comment
Assay MTb
Strain
MIC
µg/ml
%
Inhib
Where,
R =
Activity
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INTRODUCTION
The amino-thiadiazole ring is prominent structural motif found in numerous
pharmaceutically active compounds. Due to the rich pharmacological activity, amino-
thiadiazole framework plays an essential role in biologically active compounds and
therefore, represents an interesting template for medicinal chemistry.
Indeed, amino-thiadiazole based derivatives have shown several biological
activities like antiinflammatory, antitumor, antitubercular, anticonvulsant, hypnotics, CNS
depressaant and also used as herbicidal and fungicidal. In current era many amino-
thiadiazole derivatives have been synthesized and applied in medical practice.
SYNTHETIC ASPECTS
There are various methods for  obtaining aminothiadiazoles as cited in literature.103-108
General account of the summary of the reaction between isothiocyanate and
triazole shown in reaction below.
1. Q. Bano & co-workers109 have synthesized amino-thiadiazole derivatives
using isothiocyanates.
R' N
C S
+
N
N N
NH2
R SH N
N N
NH
R SH
NH R'
S
DMF
N
N N
N
R S
NH
R'
DMF
stirring
R=R'=Aryl,alkyl
K2CO3
R O
CH2
N N
N
SH
NH2
R' N
C S R O
CH2
N N
N S
N NH
R'
(I)
(II)
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THERAPEUTIC IMPORTANCE
Amino-thiadiazole derivatives exhibit broad spectrum of therapeutic activity.
Several biological activities associated with amino-thiadiazole derivatives have been
described as under.
1. Antibacterial110
2. Antiviral111
3. Antiinflammatory112
4. CNS depressant113
5. Amoebicidal114
6. Hypoglycemic115
7. Antihypertensive116
8. Antitubercular117
9. Antipyretic118
10. Antitumor119
11. Anthelmintic120
Takatori Yoshitarou et al.121 have claimed patent for amino-1,3,4-thiadiazole
as an antitumor agent, exhibiting improved activity particularly against malignant tumors
e.g. leukemia, sarcoma, cancer etc. Ferreira R.C. et al.122 have screened amino-
thiadiazole derivatives as a potent antimicrobial agent with curative action against
Trypnosoma Cruzi, was assayed in the Salmonella/microsome test. Hasegawa Yoshihiro
et al.123 patented  2-amino-1,3,4-thiadiazole derivatives as an antiulcer agent.
Maria H. Tsuhako et al.124 have investigated the bio-reductive activation of
Megazol [2-amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole] promoted by
ferredoxin: NADP+ oxidoreductase, rat liver microsomes and cellular fractions of
Trypnosoma Cruzi, Y strain. A series of 2-arylamino-1,3,4-thiadiazole derivatives was
synthesized and was examined for antihypertensive activity by Vio L. et al.125 C.T.
Supuran et al.126 have investigated amino-thiadiazole derivatives for their abilities to
activate the enzyme Carbonic Anhydrase (CA). It was found that the compounds
possessing free aminoalkyl moieties behaved as strong CA-II activators.
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Hatice N. Dogan et al.127 have synthesized two new series of aminothiadiazole
derivatives and have checked their possible anticonvulsant, antibacterial and antifungal
activities. Among those compounds (III) showed maximum protection and (IV) showed
antimicrobial test against Pseudomonas aeruginosa equal to that of Penicillin. Chufan
E E et al.128 tested anti-convulsant activity of 5-amino-1,3,4-thiadiazole. The compounds
exhibit potent anti-convulsant activity and low minimal motor impairment. Clerici F.
et al.129 have synthesized and screened a series of 2-amino-5-sulfanyl-1,3,4-thiadiazole
derivatives in order to evaluate their central nervous system activity. It was found that,
some of these compounds possess marked antidepressant and anxiolytic properties
comparable in efficiency to the reference drugs Imipramine and Diazepams.
Tomoyashu Ishikawa et al.130 have screened amino-thiadiazole derivatives(V)
(TAK-599) is a novel N-Phosphono drug of anti-methicillin-resistant staphylococcus
aureus (MRSA). S. Karakus et al.131 have synthesized N-phenyl-N”-[4-(5-alkyl/aryl-
amino-1,3,4-thiadiazole-2-yl)-phenyl] thiourea derivatives and tested for antitubercular
activity in vitro against Mycobacterium tuberculosis H37RV.
Samir Carvalho et al.132 have designed and synthesized aminothiadiazole
derivative (VI), a powerful trypanocidal agent Brazilizone A. The evaluation of the activity
was done against bloodstream trypomastigote forms of Trypanosoma Cruzi.
N N
S
OH
NHR
N N
S
OCOCH3
N
COCH3
R
(III) (IV)
S N
NR1NH
N
H3CH2CO
NH
O
N
O
S
CO2
S N
S
N
CH3
+
_
(TAK-599)    R1=PO(OH)2
(V)
47Aminothiadiazoles........
           Kwan-Young Jung et al.133 have synthesized and evaluated 3-(4-methoxy-
phenyl)-5-amino-thiadiazole derivatives as selective antagonists for human adenosine
A3 receptors (VII).
Erhan Palaska et al.134 have prepared substituted amino-1,3,4-thiadiazole
derivatives and evaluated as orally active antiinflammatory agent with reduced side
effects.The activity were compared with Naproxan, Indomethacin and Phenylbutazone.
Alice Borghini et al.135 have recently proposed aminothiadiazole analogues (VIII)
as a novel promising class of Adenosine A1 and A3 receptor antagonists. QSAR study
was also carried out for Adenosine A1 and A3 receptors.
Recently, a number of aminothiadiazole (IX) were synthesized  and evaluated for
their anti-proliferative activity by Joanna Matysiak et al.136 The cytotoxicity was carried
out in vitro against the four human cell lines (i) rectal, (ii) bladder, (iii) lung and (iv)
breast.
N
N
S
N N
NH
N
OH
OH
CH3
O2N
H
N S
N
NH
O
RH3CO
N
N S
N NH
O
R
R1
S
N
N
OH
OH
NH R
    R=alkyl,aryl,morpholinoalkyl
(VI) (VII)
(VIII)
(IX)
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SECTION-I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-o-CHLOROPHENYL -6-
ARYLAMINO-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
Aminothiadiazole derivatives are associated with broad spectrum of
pharmacological activity. In view of these findings, it appeared of interest to synthesise
3-o-chlorophenyl-6-arylamino-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles type-(II), by the
cyclisation of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with different aryl
isothiocyanates in DMF.
The structure of the synthesized products have been characterized by using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Type-(II)       R = Aryl
N N
N
N
S
Cl
NH R
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REACTION SCHEME
        Type-(II)             R=Aryl
N N
N
NH2
SH
Cl
O
NH NH2
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
N N
N
N
S
Cl
NH R
R-N=C=S
DMF , K2CO3
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-o-CHLOROPHENYL-6-p-METHYLPHENYLAMINO-1,2,4-
TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
 Observed
Alkane C-H str. (asym.) 2922 2975-2950 420
-CH3 C-H str. (sym.) 2852 2880-2860  “
C-H i.p.def. (asym.) 1459 1470-1435  “
C-H o.o.p. def. (sym.) 1374 1390-1370  “
Aromatic C-H  str. 3054 3080-3030  421
C=C str. 1501 1585-1480  “
C-H i.p. def. 1084 1125-1090  “
C-H o.o.p. def   832  835-810  “
Triazole C=N str. 1614 1640-1605  424
moiety C-N str. 1258 1350-1200 “
N-N str. 1021 1050-1010 420
C-Cl str.   744 600-800 422
Thiadiazole C-S-C str.   656  720-570 423
Amino -NH str. 3420 3450-3200 420
-NH str 1542 1650-1580  “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
N
N
S
Cl
NH
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 3-o-CHLOROPHENYL-6-p-METHOXYPHENYLAMINO-
1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.79 3H singlet Ar-OCH3             -
2. 6.88-6.85 2H doublet Ar-Hee’ Jde=9.08
3. 7.54-7.52 1H multiplet Ar-Hb
4. 7.62-7.60 2H double Ar-Hff’             Jde=9.12
 doublet
    5. 7.67-7.63 2H double Ar-Ha,c            -
triplet
6. 7.85-7.83 1H double Ar-Hd          Jdc=9.12
doublet
7. 11.42 1H singlet -NHg          -
a
bc
d
e
f'
e'
N
N
N
N
SCl
NH
O CH3
f
g
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EXPANDED AROMATIC REGION
MASS SPECTRUM
a
bc
d
e
f'
e'
N
N
N
N
SCl
NH
O CH3
f
g
Cl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-o-CHLOROPHENYL -6-
ARYLAMINO-1,2,4-TRIAZOLO[3,4-b]-1,3,4-THIADIAZOLES
(A) Synthesis of Potassium o-chlorobenzoyl dithiocarbamate101
See [A] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole
See [A] Part-I, Section-I (D).
(C) Synthesis of Phenyl isothiocynate.
 To a cooled solution of ammonia (90 ml, 0.88 M) in three necked flask, CS2
(43 ml, 0.71 M) was added  with stirring. It was followed by addition of aniline (55 ml,
0.60 M) from seperatory funnel. A heavy precipitate of ammonium phenyldithiocarbamate
seperated. The salt was transfered  and poured into 200ml of water. The resulting
solution was added in to 200gm (0.60 M) of lead nitrate in 400ml of water with constant
stirring and finally the product was isolated with steam distillation.
(D) Synthes is  o f  3-o-Chlorophenyl-6-methylphenylamino-1,2,4-triazolo
[3,4-b][1,3,4]thiadiazole
A mixture of  3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole (2.26 g,
0.01M), p-methylphenyl isothiocyanate (1.49 g, 0.01 M) in DMF (40 ml) and
anhydrous pottasium carbonate was stirred for 8 hrs at 70-80oC. Then the reaction
mixture was poured onto crushed ice. The precipitated solid  was filtered, washed with
water and crystllised from  DMF. Yield 66%, m.p. 118oC (C16H12ClN5S;  Required :
C, 56.22; H, 3.54 N, 20.49  Found : C, 56.37; H, 3.77; N, 20.73 %).
TLC solvent system : Ethyl acetate  : Hexane (3 : 7).
Similarly other aryl isothiocyanates have been condensed. The physical data are
recorded in Table No. 2.
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(D) Antimicrobial activity of  3-o-chlorophenyl-6-aryl amino-1,2,4-triazolo
[3,4-b][1,3,4]thiadiazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 2.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of aminothiadiazoles of type-(II) revealed that all the
compounds were able to inhibit the growth of Gram positive & Gram negative bacterial
strains.
In case of Gram positive bacterial strain, maximum activity was observed in
compounds bearing R =4-methoxyphenyl and 2-chloro,5-methylphenyl (21mm) against
B. coccus .  The s ignif icant  act ivi ty  was displayed by compounds having
R=4-methoxyphenyl and 4-chlorophenyl (21mm) against S. aureus.
In  case of  Gram negat ive bacter ia l  s t ra in,  compound subst i tut ing
R=4-chlorophenyl have fairly inhibit the growth of E.aerogenes. Almost all compounds
were found mildly active but the compounds bearing R=2-chloro,5-methylphenyl
displayed significant activity against P.aeruginosa
ANTIFUNGAL ACTIVITY
 Compounds having R=4-chlorophenyl and 2-chloro,5-methylphenyl  have shown
better activity (23mm), (21mm) respectively against A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz.greseofulvin.
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INTRODUCTION
The thiadiazines, six membered ring system, consist of two nitrogen and one sulfur
atom, was first documented by P. K. Bose137. There are four possible types : (I) 2H-
1,2,4-thiadiazines, (II) 2H-1,2,6-thiadiazines, (III) 2H-1,3,4-thiadiazines and (IV) 2H-
1,3,5-thiadiazines. The 1,3,4-isomer has been the most thoroughly investigated one due
to its high biological activity138-140 and wide spread spectrum action of its derivatives.
In recent years many thiadiazine derivatives have been synthesized and applied in medical
practice.
Including various medicinally interesting compounds, 1,3,4-thiadiazines are useful
for the synthesis of tri and tetracyclic heterocyclic compounds.
SYNTHETIC ASPECTS
Various methods for synthesizing 1,3,4-thiadiazine derivatives documented in
literature are as follows.
1. Ibrahim Yehia A  and co-workers141 have synthesized  stereospecific synthesis
of 6,7-dihydro-5H -1,2,4-triazolo[3,4-b][1,3,4] thiadiazine.
NH
S
N
1
2
3
4
5
6 NH
S
N
N
S
N
N
S
N
2H-1,2,4 2H-1,2,6 2H-1,3,4 2H-1,3,5
(V)
(I) (II) (III)
(IV)
N
N N
N
R SH
CH
Ar
+ R'-CO-CH2-Br
DMF / Et3N
NaBH4
N
N N
R
NH
S
H
H
Ar
R'
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2. Heravi  M. M. et al.142 have synthesised 1,3,4-thiadiazine by the cyclisation
of  4-amino-3-mercapto -6-methyl[1,2,4] triazine-5-one with phenacyl bromide.
3. M. Rahimizadeh et al.143 have prepared 1,3,4-thiadiazine by the reaction of
2,4-dichloro-6-methyl-5-nitropyrimidine with dithiazone.
4. Jia Guofeng and Li Zhengming144 have prepared substituted 4-arylsulfonyl-
4H-1,3,4-thiadiazin-5-(6H)-ones by the cyclization of R1-C6H4-SO2-
NH-NH-(CS)-NH-C6H4-R2 with chloroacetyl chloride.
5. Wang X-C. et al.145 have condensed 4-amino-3-2-(benzo-(b)- furyl)-5-mercapto
triazole and α-bromoacetophenone under microwave irradiation to yield
triazolothiadiazine.
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SO2 NH
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S
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N N
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6. A novel  and  facile strategy for synthesis of  substituted 2-amino-1,3,4-thiadiazine
on solid support is described  by  John Paul Kilburn and co-workers.146
7. Zhou S. N. et al147. have prepared 3-(4-ethoxyphenyl)-6-(4-methoxyphenyl)-
7H-1,2,4-triazolo[3,4-b][1,3,4] thiadizine by the reaction of 4-amino-
3-(4-ethoxyphenyl)-5-mercapto-1,2,4-triazole and 2-bromo-4’-methoxyacetophenone.
S
N
N
R1
R2
NH
O
OH
Pol O NH
F Moc
(X)
(XI)
N N
N
NH2
SHEtO + H3CO
O
Br
N N
N
NH
S
EtO
O CH3
THERAPEUTIC IMPORTANCE
Thiadiazine derivatives are actively involved in pharmacologically useful entities.
Some compounds are successfully proven to be chemotherapeutic agents, which are
described as under.
1. Antidepressant148
2. Antiinflammatory149,150
3. Cardiovascular151,152
4. Antifungal153
5. Analgesic154
6. Antimicrobial155
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B. S. Holla et al.156 have documented thiadiazine derivatives (XII) as antimicro-
bial agent. Kalluraya B. et al.157 have reported 3-substituted 7H-6-(6-bromo-3-
coumarinyl)-5-triazolo [3,4-b][]1,3,4-thiadiazine (XIII) and studied its antibacterial
activity.
Jonus Rochus et al.158 have prepared new thiadiazine derivatives useful as
phosphodiesterase IV inhibitor and cardiovascular agents (XIV). Ergenc Nedime and
co-workers159 described the synthesis and antimicrobial properties of new 6-aryl-3-
(2-furanyl)-7H,1,2,4-triazoles [3,4-b] [1,3,4] thiadiazines (XV).
Arranz Esther et al. 160 have prepared thiadiazine derivative as non nucleoside
reverse transcriptor inhibitor that  inhibit human immunodefeciency virus type-1
replication. Turan-Zitouni G. et al.161 have prepared triazolo thiadiazines (XVI) showing
analgesic activity. Renuka devi and Biradar162 have reported triazolothiadiazine
derivatives (XVII)  as anthelmintic, antiinflammatory and anticatatonic activity.
S
N N
N
CH3
R
O
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O
OCH3
OCH3
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O
NN
N
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R = H, Cl, Br
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Balladka K. et al.163 discovered novel thiadiazines and reported them as an
anticancer agent. Among all the synthesized compounds, four compounds were found to
be active against NCI-H460 (lung), MCF7 (breast), SF268 (CNS) in the preliminary
anticancer study. Vicentini C. et al.164 have demonstrated thiadiazines as fungicides.
D. Katiyar et al.165 have synthesized thiadiazines and screened for their in vitro anti-
tubercular activity against Mycobacterium tuberculosis H37Rv. Three compounds
showed antimycobacterial activity with MIC 12.5 µg/ml. Compounds were tested in
vitro against five multidrug resistant (MDR) strains of M.tuberculosis and were found
to be active. Khanum S. A et al.166 have synthesised triazolothiadiazine analogues via
multistep synthesis and the compounds were tested against variety of   fungal and bacterial
strains in comparision to Flucanazole and Chloramphenicol  respectively. K. R. Desai et
al.167 have documented antimicrobial activity of some thiadiazine derivatives. Nayyar
and Jain168 have synthesised some new thiadiazine derivatives which were used as anti
tubercular agents. ATP sensitive potassium (KATP) channels have important function in
neuroendocrine tissues, in smooth and skeletal muscles in the heart. In pancreatic beta
cells the  (KATP) channels ,which are formed by 4 ion channels (Kir 6.2) and 4
regulatory sulfonylurea receptor (SURI) control the glucose stimulated release of
insulin. Hansen J.B. et al.169 have prepared 1,3,4-thiadiazine derivatives which are
shown to be a potent  kir 6.2 / SU RI selective  (KATP)  channels opener.
Lee An Rong Taiwan 170 have patented triazolo thiadiazines (XVIII) as anti-
inflammatory agent. Dawood K. M. et al.171 have investigated new 1,3,4-thiadiazine
derivatives and evaluated them as antimicrobial agent.
Nadkarni et al.172 have investigated anthelmintic activity of 1,3,4-thiadiazines.
Sheena Shashikanth et al.173 have synthesised thiadiazine derivatives and tested their
antimicrobial activity against variety of fungal and bacterial strains in comparison to
Fluconazole and Chloramphenicol, respectively.
N
N
S
N
N
R
EtOOC
(XVIII)
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Shiradkar M. and Shiva Prasad 174 have documented triazolothiadiazine and
evaluated them as antibacterial, antifungal and antitubercular agent.  Karnik A. V.
et al.175 have investigated chemoselectivity of novel hetero cyclopenta [b] chrysene
derivatives namely 6-aryl-2-2a-dihydro-naptho[2’,1,5,6] pyrazo[4,3-e] [1,2,4]
triazolo[3,4-b][1,3,4]thiadiazines and studied their antimicrobial activity and molecules
exhibited good to excellent activity as compared to standard drug. Spalinska K et al.176
have synthesised some novel thiadiazines and checked for their antibacterial activity.
In view of the potential biological activities of 1,3,4-thiadiazine ring system, it
was of interest to prepare some novel derivatives of this family of heterocyclic ring bearing
triazole nucleus, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 5’-ARYL
  -5-o-CHLOROPHENYL-[3,4-b]-1,2,4-TRIAZOLO[1’,3’,4’]-
 THIADIAZINES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5’-ARYL-5-o -
CHLOROPHENY-[3,4-b]-1,2,4-TRIAZOLO-[1’,3’,4’]- THIADIAZINES
1,3,4-Thiadiazines represent one of the most active class of compounds
possessing a wide spectrum of biological activities, such as significant in vitro activity
against unrelated DNA and RNA viruses including polio and herpes viruses, diuretic,
antitubercular, spermicidal etc. In view of these facts, it was contemplated to synthesise
thiadiazine derivatives of type-(III) by condesation of 3-mercapto-4,N-amino-5-o-
chlorophenyl-1,2,4-triazole with different substituted phenacyl bromides.
The structures of the synthesised products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Some compounds have been found to have moderate activity as compared to known
antibiotics recorded on graphical chart No-3.
N N
N
N
S
R
Cl
Type-(III)         R = Aryl
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N N
N
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N
N
S
R
Cl
REACTION SCHEME
        Type -(III)         R=Aryl
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF  5’-(p-METHYLPHENYL)-5-o-CHLOROPHENYL-
[3,4-b]-1,2,4-TRIAZOLO -1’,3’,4’-THIADIAZINE
 Observed
Alkane C-H str. (asym.) 2924 2975-2950 420
-CH3 C-H str. (sym.) 2898 2880-2860 “
C-H i.p.def. (asym.) 1453 1470-1435 “
C-H o.o.p. def. (sym.) 1366 1390-1370 “
Aromatic C-H  str. 3065 3080-3030 421
C=C str. 1569 1585-1480 “
C-H i.p. def. 1124 1125-1090 “
C-H o.o.p. def 833     835-810 “
Triazole C=N str. 1597 1612-1593 420
moiety C-N str. 1191 1220-1020 422
N-N str. 1058 1050-1010 420
C-Cl str 780 800-600 423
Thiadiazine N-N str. 1036 1050-1010 “
C-N str. 1191 1220-1020 421
C-S str. 675 700-600 424
Type    Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
20.0
40.0
60.0
80.0
100.0
%T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
 558.4
 675.0
 780.2
 833.2
 969.2
1036.7
1058.8
1124.4
1191.9
1306.7
1366.5
1413.7
1453.3
1469.7
1569.9
1597.92898.8
2924.8
3065.6
N N
N
N
S
CH3
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 5’-(p-CHLOROPHENYL)-5-o-CHLOROPHENYL-
[3,4-b]-1,2,4-TRIAZOLO -1’,3’,4’-THIADIAZINE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference
   J Value
    In Hz
1. 4.04 2H singlet -CH2h         -
2. 7.46-7.42 3H multiplet        Ar-Hb+ee’                 -
3. 7.560-7.489 2H multiplet Ar-Ha,c         -
4. 7.69-7.66 1H double Ar-Hd   J
dc
- 9.2
doublet
5. 7.78-7.61 2H doublet Ar-Hff ’   J
ff’
- 8.8
N N
N
N
S
Cl
Cl
a
b
c
d
e
f
e'
f'
h
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EXPANDED AROMATIC REGION
MASS SPECTRUM
N N
N
N
S
Cl N N
N
N
S
Cl
Cl
a
b
c
d
e
f
e'
f'
h
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5’-ARYL-5-o-
CHLOROPHENYL)-[3,4-b]-1,2,4-TRIAZOLO[1’,3’,4’]-THIADIAZINES
(A) Synthesis of Potassium o-chlorobenzoyl dithiocarbamate101
See [A] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-o-dichlorophenyl-1,2,4-triazole
See [A] Part-I, Section-I (D).
(C) Synthesis of  5’-p-Methoxyphenyl -5-o-chlorophenyl-[3,4-b]- 1,2,4-
triazolo[1’,3’,4’]-thiadiazines
A mixture of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole (2.26 g,
0.01 M) and p-methoxyphenacyl bromide (2.28 g, 0.01 M) in dry methanol (50 ml) was
heated under reflux  for 5 hrs, then cooled and neutralised with aqueous pottasium
carbonate solution. The solid thus separated out was filtered, washed with water and
crystllised from ethanol. Yield 52%, m.p. 138oC (C17H13ClN4OS; Required : C, 57.22;
H, 3.67; N, 15.70;  Found : C, 57.46; H, 3.86; N, 15.97%)
TLC solvent system : Ethyl acetate  : Hexane (3 : 7).
Similarly other phenacyl bromides have been condensed. The physical data are
recorded in Table No. 3.
(D) Antimicrobial activity of 5’-aryl -5-o-chlorophenyl-[3,4-b]-1,2,4-triazolo
[1’,3’,4’]-thiadiazines
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 3.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all the thiadiazine derivatives
of type-(III) markedly  inhibit the growth of Gram positive & Gram negative bacterial
strains.
However, comparatively significant activity was observed in compounds with
R=4-chlorophenyl and 2,4-difluorophenyl against B.coccus. 2,4-difluorophenyl also fairly
inhibit the growth of S.aureus, zone of inhibition displayed by these compound is 21mm.
In case of Gram negative bacterial strain,compounds bearing R=4-chlorophenyl
show significant activity against E.aerogenes. Almost all  compounds were found mildly
active against P.aeruginosa, the compounds bearing R= 4-methoxyphenyl (20mm),
4-fluorophenyl (20mm) show better activivity.
ANTIFUNGAL ACTIVITY
 All the compounds were active against A. niger. Maximum activity was shown
by the compounds bearing R=4-fluorophenyl (23mm) and 2,4-difluorophenyl (21mm).
The antimicrobial activity shown by the compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz.greseofulvin.
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INTRODUCTION
The thiadiazepine ring system has one sulphur and two nitrogen atoms at 1,3,4-
position (I) in seven membered heterocyclic ring system. Due to the presence of the
-N=C-S group, thiadiazepines have been found highly potential for pharmaceutical
industries and also shows various biological activities177.Chemical properties of 1,3,4-
thiadiazepine derivatives have been reviewed in the last few years. However the usefulness
of thiadiazepine as a previledged system in medicinal chemistry has prompted the advances
on the therapeutic potential of this system.
Thiadiazepines act as an intermediate for the preparation of substituted
caprolactum, useful for the treatment of HIV disease.178
SYNTHETIC ASPECTS
Various methods for the synthesis of thiadiazepine derivatives are described as
under.
1. Chloro acet icacid cycl ised with Ph.NH.NH.CS.NH2 in ref luxing AcOH
containing NaOH yielded 2-amino-4-phenyl-6H,7H-1,3,4-thiadiazepin-5-one.179
2. Sinegibskaya A. D. et. al.180 have synthesised thiadiazepine by reaction of
4-amino-3-hydrazino-1,2,4-triazoline-5-thione with α-and β-dicarbonyl
compounds followed by the treatment of Br-CH2-CO-Ph.
N N
S 1
7
6
5
4 3
2
(I)
NH
NH
SNH2
Ph
+
CH2
HOOC
CH2
Cl
N
N
SNH2
Ph O
(II)
76Thiadiazepines......
3. M. Kidwai et al.181 have synthesized novel 1,3,4-thiadiazepine by the reaction of
1-amino-2-mercapto-5-substituted triazole and substituted chalcones on basic
alumina under microwave irradiation.
4. Hassan A.  et al.182 have prepared 7-amino-2-organylimino-2,3-dihydro -1,3,4-
thiadiazepine-5,6-dicarbonitrile by the reaction of thiosemicarbazide and
tetracyanoethene in ethyl acetate with admission of air.
5. R.Gururaja et al.183 have synthesised quinoline thiadiazepine derivatives by
condensation of 2-chloro-6-substituted quinoline-3-carboxaldehyde with
thiocarbohydrazide in pyridine.
R
NH NH
NH2
S
+
N
NN
N
S
N
H
N
NH2
NHR
N
N
Ethyl acetate
air
(V)
N
H
N
N N
NNH2
S
CH3
CH3
BrCH2COPh
N
N
N NN
N
S
CH3
CH3Ph
(III)
N
N N
NH2
R SH + N
N N
R S
NH
H
O
C6H4-R'
C6H4-X
C6H4-R'
C6H4-X (IV)
R CHO
Cl
+ S
NH
NH2
NH
NH2
Pyridine
N
S
N
NH
R
NH2(VI)
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6. OM Prakash et al.184 have prepared thiadiazepines by Michael type addition
of 4-amino-3-mercapto-1,2,4-triazole to α , β,-unsaturated carbonyl compounds.
THERAPEUTIC IMPORTANCE
Literature study shows that 1,3,4-thiadiazepines are known to possess better
pharmaceutical importance. The important therapeutic activities are described as under.
1. Antitumor185
2. Antidepressant186
3. Antiviral187
4. Antiarrythmic188
5. Antipsychotic189
6. Antibacterial190
7. Anti HIV191
8. CCK antagonists192
9. Anticonvulsant193
10. Gastrin receptor antagonists194
Denis195 have investigated thiadiazepines (VIII) useful as angiotensin converting
enzyme (ACE) inhibitors and Jordi  Bolos et al.196 reported  them as an important
class of antihypertensive drug.
NH
S
N
N
O COOH
COOH
(VIII)
N
N N
NH2
R SH
+
N
N N
R S
N
O
R'
R'
(VII)
78Thiadiazepines......
Rao K. Srivastava et al.197 have synthesized pyrazolo-[4,3-f]-1,2,4-triazolo[3,4-b]-
1,3,4-thiadiazepines (IX) and tested their antibacterial, antifungal, antiinflammatory and
analgesic activities. Sawanishi Hiroyuki et al.198 have reported thiadiazepines as potent
anticancer agents.  An anti-inflammatory activity of new thiadiazepine derivatives have
patented by Puodzhyunajte B. A.199 et al. and Nakhmanovich A. S.200 U. V. Laddi
and co-workers201 have prepared triazolo-thiadiazepines (X) and tested for their anti
microbial and antituberculosis activities.
Vice Susan F.202 have prepared di-indolo thiadiazepine compounds as inflammations
inhibitors, neoplasm inhibitors and pharmaceuticals for psoriasis  treatment. Non-nucleoside
reverse transcripatase activity of some thiadiazepines has been described by Artico Marino
et. al.203 Rodgers James et. al.204 have suggested cyclic urea-HIV protease inhibitors
activity of some 1,3,4-thiadiazepine derivatives. M. Ghorab and co-workers205 have
suggested thiadiazepine derivatives as antifungal agents. M.Kidwai et al.206 have reported
thiadiazepines as potential  antimicrobial agent. Ammar Y A. et al.207 have discovered
thiadiazepine derivatives  as possible potential drug for fungal infection. Elevated levels
of tumor necrosis factor alpha(TNF-alpha) have been associated with several inflammatory
disease so,Cherney R J et al.208 designed and synthesised the compounds which is
used as  potent and selective TACE inhibitors. Most of the synthesised compounds
were assessed in the human peripheral blood mono nuclear cell assay (PBMC) and the
human whole body assay (WBA) to determine their ability to suppress TNF alpha.
Ashutosh Singh and Nizamuddin209 have prepared thiadiazepines (XI) and reported
their molluscicidal activity. R.Gururaja et al.210 have documented anthelmintic activity of
1,3,4-thiadiazepine(XII).
S
N
N
N
N
CH3
R
(X)
N
N N
N
S
Ar
R
C6H5
(IX)
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Lebegue N et al.211 have synthesised novel thiadiazepine derivatives.These
molecules were evaluated for their antiproliferative activity toward the murine L1210
leukemia cell  line. The 4-methoxyphenylethyl substituted on the pyridinyl nitrogen of
the benzo pyrido-thiadiazepines  are found to be essential for the antiproliferative activity.
Kalluraya B et al.212 have synthesised  thiadiazepines and screened for their antibacterial
activities. Most of the synthesised compounds showed significant activity against both
Gram positive and Gram negative bacterial strain.
Recently, Anshu Dandia et al.213 have discovered thiadiazepines (XIII) and
screened for their antifungal activity. Kamble R and Sudha B.214 have prepared novel
1,3,4-thiadiazepines and reported them as cardiovascular agent.
Thus, significant biological properties associated with thiadiazepine derivatives
have aroused considerable interest to design the compounds in which therapeutically
active triazole nucleus is incorporated and to study their pharmacological profile, which
have been described as under.
SECTION-I :SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-o-
CHLOROPHENYL-1,2,4-TRIAZOLO [3,4-b] SUBSTITUTED
QUINOLINO [2’,3’-f]-1”,3”,4”-THIADIAZEPINES
N
N
N
R
CH3
H
H
R
(XIII)
O CH2
N
N N
N
S
CH3
CH3
R
(XII)
N
S
N
NH N
R2
R1
(XI)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-o-CHLOROPHENYL-1,2,4-
TRIAZOLO [3,4-b] SUBSTITUTED QUINOLINO [2’ ,3’ - f ] -1” ,3” ,4”-
THIADIAZEPINES
During  the past years, considerable evidence has been accumulated to
demonstrate the efficiency of 1,3,4 thiadiazepines. To further assess the potential of
such a class of compounds, thiadiazepine derivatives of type-(IV) have been synthesised
by one pot reaction of  3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with
substituted  2-chloro-3-formyl-quinolines in the presence of K2CO3.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Some compounds have been found to have moderate activity as compared to known
antibiotics recorded on graphical chart No-4.
N
N N
N
N
S
Cl
X
Type-(IV)     X = Substituents
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N N
N
NH2
SH
Cl
O
NH NH2
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
N
N N
N
N
S
Cl
NCl
OHC
X
X
DMF
K2CO3
REACTION SCHEME
        Type-(IV)     X = Substituents
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
 Observed
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDY OF 5-o-CHLOROPHENYL-1,2,4-TRIAZOLO [3,4-b]-
6-METHYLQUINOLINO [3’,2’-f]-1”,3”,4”-THIADIAZEPINE
Alkane C-H str. (asym.) 2921 2975-2950 420
-CH3 C-H str. (sym.) 2866 2880-2860  “
C-H i.p.def. (asym.) 1494 1470-1435  “
C-H o.o.p. def. (sym.) 1329 1390-1370  “
Aromatic C-H  str. 3057 3080-3030 421
C=C str. 1519 1585-1480  “
C-H i.p. def. 1074 1125-1090  “
C-H o.o.p. def   819    835-810  “
Triazole C=N str. 1616 1612-1593 420
moiety C-N str. 1242 1350-1200 423
N-N str. 1029 1050-1010 420
C-Cl str.   752    600-800 422
Thiadiazepine C-S-C str.   698                      720-570 424
20.0
40.0
60.0
80.0
100.0
120.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 480.2
 596.0
 698.2
 752.2
 819.7
 923.8
1029.9
1074.3
1128.3
1242.1
1323.1
1448.4
1494.7
1519.8
1616.2
2237.3
2866.0
2921.9
3057.0
N
N N
N
N
S
Cl
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF  5-o-CHLOROPHENYL-1,2,4-TRIAZOLO [3,4-b]-
6-METHOXYQUINOLINO [3’,2’-f]-1”,3”,4”-THIADIAZEPINE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.92 3H singlet Ar-OCH3          -
2. 7.53-7.51 1H double Ar-Ha       Ja,b-9.2
doublet
3. 7.42-7.37 2H multiplet Ar-Hb,c          -
4. 7.90-7.88 1H double Ar-Hd      Jc,d-6.8
doublet
5. 7.34-7.32 1H double Quinoline-Hh      Jh,i-9.2
doublet
6. 7.15-7.14 1H doublet Quinoline-Hg      Jg,h-4.07
7. 7.67-7.65 1H doublet Quinoline-Hi      Ji,h-8.09
8. 7.74 1H singlet             Thia’pine N=CHe          -
9. 8.52 1H singlet Quinoline-Hf          -
N
N N
N
N
S
O
CH3
Cl
a
b
c
d
e
f
g
h
i
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EXPANDED AROMATIC REGION
MASS SPECTRUM N
N N
N
N
S
O
CH3
Cl
a
b
c
d
e
f
g
h
iN
N N
N
N
S
Cl
CH3
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5 -o-CHLOROPHENYL-
1,2,4-TRIAZOLO [3,4-b] SUBSTITUTED QUINOLINO [2’,3’-f]-1”,3”,4”-
THIADIAZEPINES
(A) Synthesis of Potassium o-chlorobenzoyl dithiocarbamate101
See [A]  part-I,  section-I  (C)
(B) Synthesis of 3-Mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole
See [A]  part-I,  section-I  (D)
(C) Synthesis of Substituted 2-chloro-quinoline-3-carboxaldehydes215
These were prepared by the reaction of substituted acetanilide with DMF
and POCl3 using a well known Villsmeierhaack rearrangement.
(D) S y n t h e s i s  o f  5 - o - c h l o r o p h e n y l - 1 , 2 , 4 - t r i a z o l o [ 3 , 4 - b ]  m e t h o x y
quinolino[2’,3’-f]-1",3",4"-thiadiazepines
A mixture of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole (2.26 g,
0.01M), 2-chloro-3-formyl-6-methoxy quinoline (2.20g, 0.01M) in dry DMF (20 ml)
and anhydrous K2CO3 (2.09 g) was refluxed at 80oC for 4 hrs. It was cooled and
poured onto crushed ice. The product was isolated and crystallised from ethanol. Yield
58%, m.p. 148oC C19H12ClN5OS ; required : C, 57.94; H, 3.07; N, 17.78, found :
C, 58.08; H, 3.23; N,17.97%.
TLC solvent system : Ethyl acetate : Hexane (4 : 6).
Similarly other substituted 1,3,4-thiadiazepines were synthesised. The
physical data are recorded in Table No. 4.
(E) Antimicrobial  act ivity of  5-o -chloropheny -1,2,4-triazolo[3,4-b]
substituted  quinolino [2’,3’-f]-1",3",4"-thiadiazepines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 4.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that 1,3,4 thiadiazepine
derivatives of type-(IV) were found to be moderately active against Gram positive
bacteria B. coccus.and S. aureus,and also shown promising activity against Gram
negative bacteria like E.aerogenes and P.aeruginosa..
The maximum activity was observed in compound bearing R=8-methylquinolinyl
and 6-methoxyquinolinyl against  S. aureus. The significant activity was observed in
compounds having R=8-methoxyquinolinyl and 8-chloroquinolinyl substituents against
B. coccus.
In case of  E.aerogenes all the  compounds were least active, while the
compounds bearing R=6-methoxyquinolinyl and 8-methoxyquinolinyl displayed better
activity. The compound having  8-chloroquinolinyl have shown good activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate activity against A. niger.  The compounds
having R=6-chloroquinolinyl and 8-chloroquinolinyl showed highest activity against
A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz.greseofulvin.
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INTRODUCTION
Mannich reaction consists of the condensation of ammonia or primary/secondary
amine, usually as the hydrochloride, with formaldehyde or other aldehyde, and a
compound containing atleast one hydrogen atom of pronounced reactivity.
In 1912, Carl Mannich has investigated this reaction. Today, due to its wide
range of biological activities, much interest has been focused on this reaction. Mostly,
they are found to be antineoplastic, analgesic and antibiotic agents. Mannich bases are
also employed as an intermediate in industrial chemical synthesis.
SYNTHETIC ASPECTS
Various substrates216-221 have been used to synthesize Mannich bases as cited
in literature described as under.
1. B.Shivarama Holla et al.222 have prepared Mannich base derivative by amino
methylation of 3-substituted 4-[5-(4-methoxy-2-nitrophenyl)-2-furylidenes]
amino-5-mercapto-1,2,4-triazole with formaldehyde and various secondary
amines.
N
NN
H
N
O
NO2
H3CO
RS
ONH
HCHO
N
NN
N
O
NO2
H3CO
RS
NO
(I)
2. Venkatesha Prabhu G. et al.223 have prepared amino Mannich bases by
the condensation between benzylated heterocyclic secondary amines, benzaldehyde
and urea.
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CHO
+
N
H
X
NX OH
H
Urea
NX NH
H
O
NH XN
H
R
R R R
3. Fox , Raymond C. et al.224 have reported the preparation of some novel metal
selective Mannich base.
4. Ulrich Girreser et al.225 have synthesised Mannich base by the reaction of
7-aryl-5,6-dihydro pyrido[2,3-d]pyrimidine(1H,3H)-2,4-diones , phosphorous
oxychloride and N,N-dimethyl formaldehyde.
5. Suman Sahoo et al.226 devoloped an efficient process for a simple and fast
reaction of different aldehydes , ketones amines to afford corresponding Mannich
base using catalytic amount of ionic liquid.
MECHANISM
This reaction is an example of nucleophilic addition of an amine to a carbonyl
group followed by elimination of a hydroxyl anion to the Mannich base. The probable
mechanism of this reaction is described as under.
N
N
N
O
CH3
O
CH3
Ar
DMF/POCl3
15 Min
r.t.
2H2O N
N
N
O
CH3
O
CH3
Ar
NMe2
(III)
(II)
(IV)
O
+
NH2
+
O CH3
Ionic Liquid
r.t.
NH
92Mannich Bases......
THERAPEUTIC IMPORTANCE
It has been well established that Mannich bases possess valuable biological
activities including,
1. Antiherpes227
2. Antileukemic228
3. Antitumor229
4. Antileishmanial230
5. Antipsychotic231
6. Antibacterial232-234
7. Antiinflammatory235
8. Cytotoxic activity236
9. Anticonvulsant237
Shingare M. S. et al.238 have reported the synthesis and the antiviral activity of
some Mannich bases(V). Holla B. S. et al.239 have documented some 3-substituted-1-
(aminomethyl)-4-[5-(4-nitrophenyl-2-furfurylidene)-amino]-1,2,4-triazol-5-thiones(VI)
and tested their antibacterial activity.
NN
S
NH
N
S
N
S
R
R
N
N
N
N
R'
O
NO2
R
R’=morpholino 4-methyl
piperazinyl piperidine
(V) (VI)
R
NH
R1
. . + CO
H
H
R1
N C
H
HR
R1
N C
H
H
OH
R1
N+ CH2
R RH
+
OH
_
R1
N C
H
HR
+
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Kawabe Tatoshi and co-workers240 have synthesized some Mannich bases
exhibiting antihypertensive, blood-flow increasing and blood aggregation inhibition
effect.  Surendra Pandeya and co-workers 241 have synthesised Mannich bases of
norfloxacin. Investigation of in vitro antimicrobial activity of these compounds was taken
by agar dilution method against 28 pathogenic bacteria , 8 fungi and anti HIV activity
against replication of  HIV-1 in MT-4 cells. All the synthesised compound are more
active than norfloxacin and also more active than the standared drug. Two compounds
have shown inhibition against HIV-1 with EC50 value of 11.3 and 13.9 µg/ml. Balkrishna
kalluraya et al.242 constructed Mannich base derivatives and reported its use as
antibacterial and antifungal agents. Maria Grazia et al.243 have discovered novel Mannich
bases btained by aminoalkylation of 3H-pyrrolo [3,2-f]quinoline and reported them as
potential vasorelaxing agents.
Halis Suleyman et al.244 discovered 3-benzoyl-methyl-4-phenyl-4-piperidinol
hydrochloride and tested them as antiinflammatory agent which showed their effect in
acute and chronic phase of inflammation, respectively. Sheela Joshi et al.245 have
prepared Mannich bases of isoniazide which showed better antitubercular activity than
isoniazide. Francisca Lopes et al.246 have prepared a novel Mannich bases which
displayed antimalarial activity against the multi drug resistance plasmodium falciparum
strain Dd2 and demonstrated no significant loss in activity compared to Amodiaquine.
Sarvesh Vashistha et al.247 have documented Mannich base and reported them as useful
anticonvulsant agent. Cogan P.S.et al.248 have synthesised some new Mannich base
derivatives and reported them as anticancer agent. Nable A. et al. 249 have synthesised
Mannich base and excellent fungicidal results were obtained against the various types of
fungi under investigation.
OH
N
CH3 CH3
(VII)
N
HCl S
N
CH3
CH3
(VIII)
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Jingli Wang et al.250 have investigated new derivatives of Mannich bases (VII)
and evaluated them as anticancer agent. Mohammad Abid and Amir Azam 251 have
discovered some novel Mannich base derivatives (VIII) and the antiamoebic activities
of these compounds were evaluated by microdilution method  against HM1 : 1 MSS
strain of Entamoeba Histolytica. Dharmarajan Shriram et al.252 have synthesised
Mannich base of isoniazide and screened for antimycobacterial activity and the synthesised
compounds were found to be most active than isoniazide. W. Malinka et al.253 have
prepared a series of  new 4-aryl piperazine derivatives of isothiazolo pyridine of Mannich
base and assayed as potential analgesic agent. Pharmacological  assay demonstated that
all the compounds displayed significant activity in the mouse writhing assay.
Recently, Ahmed  Aborai et al.254 have synthesised a series of 5-(2-hydroxyphenyl)-
3-substituted -2,3-dihydro-1,3,4-oxadiazole-2-thione derivatives (IX) and evaluated
for their in vitro anticancer activity. Seven of the investigated compounds displayed
high activity in primary assay and compounds were identified as promising lead compounds.
Dharmarajan and co-worker 255 have synthesised a series of pyrazinamide Mannich
base (X) and evaluated them for antimycobacterial  activity in vitro and in vivo against
Mycobacterium Tuberculosis H37Rv. In the in vivo animal model decreased the
bacterial load in lung and spleen tissues. Mohmmad Abid et al.256 have synthesised Mannich
base  derivatives and subjected to evaluation for their antiamoebic activity. Compound
was found to be a better inhibitor of  Entamoeba Histolytica as compared to
Metronidazole.
O
N N
OH
S
R
(IX)
N
N
NH N
N
Ar
O
(X)
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Keeping in view of these valid observations prompted us to combine this nucleus
with N-bridged nitrogen heterocycles, so as to enhance the overall activities of resulting
moiety, which have been described as under.
SECTION-I :SYNTHESIS AND BIOLOGICAL EVALUATION OF  4,N-SUB-
STITUTED BENZALAMINO-3-MERCAPTO-5-o-CHLORO-
PHENYL-1,2,4-TRIAZOLES
SECTION-II :SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-[BIS-ARYL/
A L K Y L - A M I N O M E T H Y L ] - 5 - o - C H L O R O P H E N Y L - 4 -
          S U B S T I T U T E D  B E N Z A L A M I N O - 2 , 3 - D I H Y D R O -
[1,2,4]TRIAZOL-3-THIONES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4,N-SUBSTITUTED
BENZALAMINO-3-MERCAPTO-5-o-CHLOROPHENYL-1,2,4-TRIAZOLES
Azomethine derivatives represent one of the most active classes of compounds
having a wide spectrum of  biological activities. Hence it was considered worthwhile to
synthesise azomethine derivatives of type-(V) for better drug potential. The azomethine
derivatives were synthesised by the condensation of  3-mercapto-4,N-amino-5-o-
chlorophenyl-1,2,4-triazole with different aromatic aldehydes in the presence of
sulphuric acid.
The structure of the synthesised products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Some compounds have been found to possess moderate activity as compared to known
antibiotics recorded on graphical chart No-5.
Type-(V)             R = Aryl
N N
N
N
R
Cl
SH
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N N
N
NH2
SH
Cl
O
NH NH2
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
R-CHO
N N
N
N
R
Cl
SH
Con. H2SO4
REACTION SCHEME
        Type - (V)                   R=Aryl
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF  4,N-p-METHOXYBENZALAMINO-3-MERCAPTO-5-o-
CHLOROPHENYL-1,2,4-T R I A Z O L E
 Observed
Alkane C-H str. (asym.) 2924 2975-2950 420
-CH3 C-H str. (sym.) 2874 2880-2860  “
C-H i.p.def. (asym.) 1411 1470-1435  “
C-H o.o.p. def. (sym.) 1359 1390-1370  “
Aromatic C-H  str. 3054 3080-3030 421
C=C str. 1570 1585-1480  “
C-H i.p. def. 1110 1125-1090  “
C-H o.o.p. def   838     835-810  “
Triazole C=N str. 1605 1612-1593 420
moiety C-N str. 1168 1220-1020 423
N-N str. 1049 1050-1000 424
C-Cl str.   725     600-800  “
C-S str.   646                       700-600 422
Ether C-O-C str. (asym.) 1255  1275-1200  “
C-O-C str. (sym.) 1027  1075-1020  424
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N N
N
N
O CH3
Cl
SH
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 4,N-p-METHOXYBENZALAMINO- 3-MERCAPTO-5-o-
CHLOROPHENYL-1,2,4-T R I A Z O L E
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.84 3H singlet Ar-OCH3          -
2. 5.25 1H singlet N=CHg          -
3. 6.91-6.89 2H doublet Ar-Hee’ Jee’-f=8.11
4. 7.41-7.37 1H multiplet Ar-Hb          -
5. 7.50-7.47 2H multiplet Ar-Ha,c          -
6. 7.56-7.53 1H double Ar-Hd
doublet
7. 7.68-7.66 2H doublet Ar-ff’ Jff’-e=8.
a
c
d
N N
N
N
Cl
SH
O CH3
b
e
e'
f
f'
g
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EXPANDED AROMATIC REGION
MASS SPECTRUM
a
c
d
N N
N
N
Cl
SH
O CH3
b
e
e'
f
f'
g
N N
N
N
Cl
S
O 3
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4,N-SUBSTITUTED
BENZALAMINO-3-MERCAPTO-5-o-CHLOROPHENYL-1,2,4-TRIAZOLES
(A) Synthesis of Potassium o-chlorobenzoyl dithiocarbamate101
See [A] Part-I, Section-I (C).
(B) Synthesis of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole
See [A] Part-I, Section-I (D).
(C) Synthesis of 4,N-p-Methoxybenzalamino-3-mercapto-5-o-chlorophenyl-1,2,4-
triazoles
A mixture of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole (2.26 g,
0.01 M), p-methoxybenzaldehyde (1.36 g, 0.01 M) in absolute alcohol (25 ml) in
presence of sulphuric acid as a catalyst were refluxed for 8 hrs, then cooled and poured
on to crushed ice. The solid thus separated out was filtered, washed with water and
crystllised from ethanol. Yield 68%, m.p. 138oC (C16H13ClN4OS; Required : C, 55.73;
H, 3.80; N, 16.25;  Found : C, 55.97; H,3.96; N, 16.43%).
TLC solvent system : Ethyl acetate  : Hexane (2 : 8).
Similarly other derivatives have been synthesised. The physical data are recorded
in Table No. 5.
(D) Antimicrobial activity of 4,N-substituted benzalimino-3-mercapto-5-
(o-chlorophenyl)-1,2,4-triazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 5.
103Mannich Bases......
   
 S
r.
   
 R
  M
ol
ec
ul
ar
   
M
ol
ec
ul
ar
   
   
M
. P
.
   
   
  R
f*
   
 Y
ie
ld
   
  %
 o
f N
it
ro
ge
n
   
 N
o.
   F
or
m
ul
a
   
  W
ei
gh
t
   
   
  o
C
   
   
V
al
ue
   
   
%
   
   
   
   
C
al
cd
.  
   
   
Fo
un
d
1
   
 2
   
   
 3
   
   
   
4
   
   
   
5
   
   
   
6
   
   
   
   
   
  7
   
   
   
   
   
 8
   
   
 9
*T
LC
 S
ol
ve
nt
 S
ys
te
m
 : 
Et
hy
l a
ce
ta
te
:H
ex
an
e 
(2
:8
)
5a
4-
O
C
H
3-
C
6H
4-
  C
16
H
13
C
lN
4O
S
   
34
4.
5
 1
38
0.
56
68
   
16
.2
5
   
  1
6.
43
5b
4-
C
H
3-
C
6H
4-
  C
16
H
13
C
lN
4S
   
32
8.
5
 1
54
0.
60
63
   
17
.0
4
   
  1
7.
26
5c
4-
O
H
-C
6H
4-
  C
15
H
11
C
lN
4O
S
   
33
0.
5
 1
30
0.
54
54
   
16
.9
4
   
  1
7.
08
5d
4-
C
l-
C
6H
4-
  C
15
H
10
C
l 2
N
4S
   
34
9
 1
46
0.
78
70
   
16
.0
4
   
  1
6.
19
5e
4-
F-
C
6H
4-
  C
15
H
10
C
lF
N
4S
   
33
2.
5
 1
94
0.
72
55
   
16
.8
4
   
  1
6.
99
5f
3-
O
H
-C
6H
4-
  C
15
H
11
1C
lN
4O
S
   
33
0.
5
 1
12
0.
66
49
   
16
.9
4
   
  1
7.
09
5g
2-
C
l-
C
6H
4-
  C
15
H
10
C
l 2
N
4S
   
34
9
 1
26
0.
80
66
   
16
.0
4
   
  1
6.
97
5h
2-
N
O
2-
C
6H
4-
  C
15
H
10
C
lN
5O
2S
   
35
9.
5
 1
74
0.
66
57
   
19
.4
6
   
  1
9.
78
5i
2-
O
H
-C
6H
4-
  C
15
H
11
1C
lN
4O
S
   
33
0.
5
 1
58
0.
62
67
   
16
.9
4
   
  1
7.
07
5j
2,
4 
di
(C
l)
-C
6H
3-
  C
15
H
9C
l 3
N
4S
   
38
3.
5
 1
42
0.
74
53
   
14
.6
0
   
  1
4.
76
5k
3,
4 
di
(O
C
H
3)
-C
6H
3-
  C
17
H
15
C
lN
4O
2S
   
37
4.
5
 1
98
0.
52
71
   
14
.9
5
   
  1
5.
13
5l
an
th
ra
-
  C
23
H
15
C
lN
4S
   
41
4.
5
 1
66
0.
48
47
   
13
.5
0
   
  1
3.
72
TA
B
L
E
-5
 :
P
H
Y
SI
C
A
L
 C
O
N
ST
A
N
T
S 
O
F
  4
,N
-S
U
B
ST
IT
U
T
E
D
 B
E
N
Z
A
L
A
M
IN
O
-3
-M
E
R
C
A
P
T
O
-5
-o
-C
H
L
O
R
O
PH
E
N
Y
L
-1
,2
,4
-T
R
IA
Z
O
L
E
S
104Mannich Bases......
051015202530
ZONE OF INHIBITION IN mm B.
 c
oc
cu
s
16
17
13
19
21
11
18
9
14
17
15
10
25
18
20
22
0
S.
 a
ur
eu
s
18
14
15
20
19
12
19
11
12
21
17
13
25
19
15
21
0
E.
ae
ro
ge
ne
s
13
18
10
14
20
16
16
12
15
21
16
14
20
21
22
19
0
P.
ae
ru
gi
no
sa
17
16
15
20
17
14
21
11
17
13
11
16
22
21
16
23
0
A
. n
ig
er
14
17
19
18
19
11
23
13
12
21
15
16
0
0
0
0
26
5a
5b
5c
5d
5e
5f
5g
5h
5i
5j
5k
5l
A
m
ox
ic
ill
in
Be
nz
oy
lp
e
ni
ci
lli
C
ip
ro
flo
xa
c
in
Er
yt
h
ro
m
y
ci
n
G
re
s
eo
fu
l
vi
n
G
R
A
PH
IC
A
L 
C
H
A
R
T
 N
O
. 5
 :
  A
N
T
IM
IC
R
O
B
IA
L 
A
C
T
IV
IT
Y
 O
F 
4,
N
-S
U
B
ST
IT
U
T
E
D
 B
E
N
Z
A
L
A
M
IN
O
-
3-
M
E
R
C
A
PT
O
-5
-o
-C
H
L
O
R
O
PH
E
N
Y
L
-1
,2
,4
-T
R
IA
Z
O
L
E
S
105Mannich Bases......
CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been concluded, that all the azomethine
derivatives of type-(V) have displayed considerable activity against  Gram positive &
Gram negative bacterial strains.
In case of Gram positive bacterial strain maximum activity was observed in
compound bearing R = 4-fluorophenyl (21mm) against B.coccus. The significant activity
was displayed by compounds having R=4-chlorophenyl and 2,4-dichlorophenyl
(20mm),(21mm) against S.aureus.
In case of Gram negative bacterial strain ,compounds  bearing R=4-fluorophenyl
and 2,4-dichlorophenyl showed good activity against E.aerogenes. Almost all
compounds were found mildly active against P.aeruginosa, maximum activity observed
in R= 4-chlorophenyl (20mm) and 2-chlorophenyl(21mm).
ANTIFUNGAL ACTIVITY
It has been found, that all the compounds were active against A. niger. Maximum
activity was shown by the compounds bearing R=2-chlorophenyl and 2,4-dichlorophenyl
(23mm), (21mm).
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz. greseofulvin.
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SECTION-II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-[BIS-ARYL/A L K Y L -
A M I N O M E T H Y L ] - 5 - o - C H L O R O P H E N Y L - 4 - S U B S T I T U T E D
B E N Z A L A M I N O - 2 , 3 - D I H Y D R O - [ 1 , 2 , 4 ] T R I A Z O L - 3 - T H I O N E S
In view of getting better therapeutic agents and considering association of various
biological activities with triazole nuclei, preparation of Mannich bases of type-(VI) have
been undertaken. Mannich bases of type-(VI) have been prepared by the condensation
4,N-substituted benzalamino-3-mercapto-5-o-chlorophenyl-1,2,4-triazole with primary/
secondary amines and formaldehyde in dioxane.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Type-(VI)         R = Aryl ,  R  ,R’ = Alkyl/Aryl
N N
N
N
R
Cl
S
N
R' R
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REACTION SCHEME
N N
N
NH2
SH
Cl
R-CHO
N N
N
N
R
Cl
SH
Con. H2SO4
R-NH2 , R-NH-R'
HCHO
N N
N
N
R
Cl
S
N
R' R
Type-(VI)         R = Aryl ,  R  ,R’ = Alkyl/Aryl
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 2-p-CHLOROANILIOMETHYL-5-o-CHLOROPHENYL-4-
p-METHOXYBENZALAMINO-2,3-DIHYDRO-[1,2,4]TRIAZOL-3-THIONE
 Observed
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
Alkane C-H str. (asym.) 2908 2975-2950  420
-CH3 C-H str. (sym.) 2837 2880-2860   “
C-H i.p.def. (asym.) 1443 1470-1435   “
C-H o.o.p. def. (sym.) 1357 1390-1370   “
Aromatic C-H  str. 3056 3080-3030   421
C=C str. 1569 1585-1480   “
C-H i.p. def. 1110 1125-1090   “
C-H o.o.p. def   837  835-810   “
Triazole C=N str. 1605 1612-1593   420
moiety C-N str. 1168 1220-1020   423
N-N str. 1027 1050-1010   420
C-Cl str.   760  600-800   422
C=S str. 1255 1250-1050   424
Ether C-O-C str. (asym.) 1213 1275-1200   420
C-O-C str. (sym.) 1027 1075-1020   “
                                              (overlapped)
N N
N
N
O
CH3
Cl
S
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 2-PIPERAZIN-1-YL-METHYL-5-o-CHLORO
PHENYL-4-p-METHOXYBENZALAMINO-2,3-DIHYDRO-[1,2,4]TRIAZOL-3-
THIONE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.84 3H singlet Ar-OCH3          -
2. 5.28 2H singlet -CH2h          -
     3. 5.72 1H singlet N=CHg          -
4. 6.89-6.91 2H doublet              Ar-Hee’                    Jef - 6.0
5. 7.38-7.42 1H multiplet Ar-Hb        -
6. 7.48-7.49 2H multiplet Ar-Ha,c        -
7. 7.55-7.56 1H triplet Ar-Hd        -
8. 7.66-7.68 2H double Ar-Hff’      Jfe - 6.0
9. 1.64 6H singlet piperidine-CH2i         -
    10. 2.88 2H singlet piperidine-CH2i’         -          -
    11. 9.99 1H singlet piperidine-NHi         -
ab
c
d
e e'
f
g
f'
h
i
N N
N
N
Cl
S
O CH3
N
N
H
ii
i'
j
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EXPANDED AROMATIC REGION
   MASS SPECTRUM
ab
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e e'
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g
f'
h
i
N N
N
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N N
N
N
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S
O
CH3
N
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-[BIS-ARYL/ALKYL-
AMINOMETHYL]-5-o-CHLOROPHENYL-4-SUBSTITUTED BENZAL
AMINO-2,3- DIHYDRO-[1,2,4]TRIAZOLE-3-THIONES
(A) Synthesis of 3-Mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole
See [A] Part-I, Section-I (D).
(B) S y n t h e s i s  o f  4 , N - s u b s t i t u t e d  b e n z a l a m i n o - 3 - m e r c a p t o - 5 - o -
chlorophenyl-1,2,4-triazole
See [A] Part-IV, Section-I (C)
(C) S y n t h e s i s  o f   2 - [p -Chloroan i l ino  methy l ] -5 -o - ch loropheny l -4 -
p-methoxybenzalamino-2,3-dihydro-[1,2,4]triazol-3-thione
A mixture of 4,N-p-methoxybenzalamino-3-mercapto-5-o-chlorophenyl-1,2,4-
triazole (3.44 g, 0.01 M), formaldehyde (0.3 g, 0.01 M) and  p-chloroaniline (1.28 ml,
0.01M) in dioxane(50 ml) was stirred for 24 hrs and kept overnight in a freeze. Then the
resulting mixture was poured on to crushed ice. The product was isolated and crystllised
from  ethanol. Yield 50%, m.p. 164oC (C23H19Cl2N5OS; Required : C, 60.06;
H, 4.62; N, 14.46;  Found : C, 60.29; H,4.87; N, 14.80%).
TLC solvent system : Acetone  : Benzene (4 : 6).
Similarly other derivatives have been synthesised. The physical data are recorded
in Table No. 6.
(D) A n t i m i c r o b i a l  a c t i v i t y  2 - [ B i s - a r y l / a l k y l - a m i n o m e t h y l ] - 5 - o -
chlorophenyl-4-substituted  benzalamino-2,3-dihydro-[1,2,4]triazol-3-thiones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 6.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that all the compounds of
type-(VI) were found to be moderately active against Gram positive bacteria
B. coccus.and S. aureus, and also shown promising activity against Gram negative
bacteria like E.aerogenes and P.aeruginosa.
The maximum activity was observed in compound bearing R=4-methoxyphenyl
against S.aureus. The significant activity was observed in compound having
R=4-chlorophenyl  against B.coccus.
In case of E.aerogenes all the  compounds were active and maximum activity
was shown by the compounds bearing  R=4-chlorophenyl, and 4-fluorophenyl (21mm),
(20mm) respectively. The compounds having R=4-fluorophenyl, and piperidinyl have
shown good activity against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited mild activity against A. niger. Compounds having
R= 4-fluorophenyl  and piperidinyl shown significant activity.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicil l in,  ciprofloxacin,  erythromycin and antifungal activity was
compared with standard drug viz. greseofulvin.
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INTRODUCTION
Imidazolinone, a five membered heterocycle having 2-nitrogen atoms at the
1 and 3-position and C=O group present at following positions : 2-oxo-imidazoline (I),
4-oxo-imidazoline (II), 5-oxo-imidazoline (III) are known.
The discovery of the 2-substituted-5’-imidazolines dates back to the year 1888,
when A. W. Hoffmann257 for the first time discovered 5-oxo-imidazolines by heating
N1-diacetylethylene diamine in a stream of dry hydrogen chloride. Furthermore, the
same compound was prepared by A. Ladenburg258 by the fusion of two equivalents of
sodium acetate with one equivalent of ethylenediamine dihydrochloride.
Imidazolinones have been found to be potent drug in pharmaceutical industries
and possess a wide spectrum of biological activities. Acetolactate synthase (ALS), the
first enzyme in the biosynthetic pathway of leucine, isoleucine and valine is inhibited by
imidazolinone herbicides like imazapic and imazaquin.
SYNTHETIC ASPECTS
Synthesis of imidazolinones have been reported in literature. Aminolysis of
oxazolone with amine yields imidazolinone, which has been reported in literature259.
1. Jean michel Lerestif et al.260 have prepared imidazolinone by cycloaddition
reaction with α-aminoester and imines.
2. Aleksey N. vasiliev et al.261 have prepared imidazolinone by the reaction of di
ethyl ester of 5-ethyl pyridine 2,3-dicarboxylic acid with 2-amino,2,3-dimethyl
butyramide in the presence of sodium hydride.
(II)
N
N
H
O
1
2
34
5
N
N
H
O N
N
H
O
(I) (III)
N
R1
EtO R2
MeOOC
+ N
R3
R4
N
N
R3
R1
O
R4
70 C
(IV)
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3. Hisato Takeuchi et al.262 have described a new synthesis of imidazolinones
by intramolecular aza-Wittig reaction, using azido substituted imides and
triphenylphosphine.
4. Feng-Jun-Cai et al.263 have reported synthesis of 5-imidazolinone derivatives by
microwaves irradiation.
REACTION MECHANISM
Reaction of azlactone with various compounds such as water, alcohols, amines
and hydrogen halides, amides of α-acylaminoacrylic acids obtained from the condensation
of azlactone and primary amine can be converted into imidazolinone derivatives as shown
in reaction.
N
COOEt
COOEtEt
+
CONH2
CH3 CH3
NH2
CH3
NaH
N
N
H
N
CH3 CH(CH3)2
O
COOEt
Et
   (V)
A
N3
O
N
R2
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O
Ph3P NA
N
O
R2
R1
A = R3 ,
N
O
O
X
R
R'- NH2
NH
NH
X
R
O
O R'
POCl3
N
N O
R
R'X
R’-NH2, DryC5H5N/Abs. C2H5OH, K2CO3
   (VI)
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THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, Xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and tolazoline
and phentolamine as adrenergic blocking agents. Various imidazolinones are known to
exhiibit a broad spectrum of biological activities as under.
1. Antiinflammatory264
2. Anticonvulsant265
3. Antihistaminic266
4. Antiparkinsonian267
5. Potent CNS depressant268
6. Antiviral269
7. Anthelmintic270
8. Antitubercular271
9. Antidiabetic272
10. Anticancer273
11. Fungicidal274
Menn JJ275 have synthesised imidazolinone derivatives and used as pesticides.
George V De Lucca276 have reported imidazolinone derivatives, which  are shown to
possess excellent HIVprotease inhibitor activity. Rama Sharma and co-workers277 have
formulated 5-oxo-imidazolines possessing potential antimicrobial activity. Keun-Jin Oh
et al.278 have investigated some novel imidazolinone derivatives, which abolised the
enzymatic activity as well as the binding affinity for the co-factor FAD (Flavin,Adenine
Dinucleotide). Kalluraya B. and co-workers279 have discovered a series of 4-(1-aryl-
5-oxo-2-phenyl-2-imidazolin-4-yl)methano-5-chloro-3-methyl-1-phenyl-3-pyrazole and
tested for their anti-inflammatory, analgesic and antibacterial activity.
Ozaki Satoshi et. al.280 have reported imidazolinones useful as analgesic,
antagonists against tolerance to narcotic analgesics typified by morphine, agents for the
treatment of obesity and drugs for ameliorating brain function. Muchii Dalsuke et. al.281
have synthesised new imidazolones as a telomerase inhibitors and antitumor agents. Imam
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Hidayat et. al.282 have reported ALS-inhibitory activity of imidazolinones. Zhong Jin283
has found imidazoline derivatives (VII) as cytoxic towards several tumor cell lines.
Solankee A.et al.284 have synthesised some imidazolinone derivatives (VIII) and
evaluated them as antitubercular agent. El-Sayed et al.285 have synthesised imidazolinone
derivatives (IX) and screened for their antibacterial and antifungal activities.
Armando Rossello et al.286 have found that imidazolinones are potential antifungal
agent. Zohar Y.et al.287 have discovered a novel imidazolinone containing compound,
which are useful tool in the search for new anti-TB drugs.The new anti-TB drug that
inhibit branched chain amino acid (BCAA) biosynthesis, as these are essential aminoacid
that are not available to a Mycobacterium during growth in an infected organism. Jean
M.R.et al.288 have discovered imidazolinones and tested as antileishmanial agents. Irene
M.L. et al.289 have investigated some imidazolinone derivatives possessing antireteroviral
activity. A series of  imidazolinone analogues was synthesised and shown to possess
potent murb inhibitory as well as antibacterial activity by Bronson J.J et al.290 Wang
J.G et al.291 have reported imidazolinones as herbicides.
NH
N
N
NH3CO
OCH3
OCH3N
O
CH3
O
(VII)
N
N
N
N
O
Ph
CH3CH3
Ph
OAr
(VIII) O
O2N
N
N
O
SO2NHR1
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CONTRIBUTION FROM OUR LABORATORY
Dr. H. H. Parekh et al.294 suggested imidazolinones as a antitubercular,
anticancer (XII) agents.
H. H. Parekh and co-workers295 have synthesised 5-oxo-imidazolines as novel
bioactive compounds derived from benzimidazole. P. H. Patel and co-workers296 have
discovered imidazolines bearing 2-amino-thiazole moiety as an antimicrobial agents.
A. R. Parikh297 have reported 5-oxo-imidazolines as biologically active agents. Hasmukh
Kanjaria and co-workers298 have described imidazolinones as potential antimicrobial
agents. Satyen P. Patel and co-workers299 have synthesised imidazolines as biologically
active agents. Joshi H.et  al .300 have synthesised imidazolinones as potent
Aleksey N. Vasiliev et al.292 have synthesised imidazolinone (X) and studied
their herbicidal activity. Mimi L.Quan et al.293 have discovered biphenyl imidazolinone
derivatives. Representative compounds (XI) were very active in lowering blood
pressure in conscious renal hypertensive rats and also useful as angiotensin II receptor
antagonist.
N
N
H
N
O
CH3
CH3
CH3
COOHR
R'
(X)
N
N
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CH3
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N
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anticonvulsant agents. Parikh et. al.301 have reported 4-(4’-arylidene-2’-phenyl-5’-
oxo-imidazolin-1’-yl)- benzophenone and screened for their antimicrobial activity.
Recently, Trucco F. et al.302 have prepared imidazolinones, which are used in
acetolactate synthase (ALS) catalyses the first common step in the biosynthesis of
branched chain amino acid in plant and is the target of several herbicides. Quivet E.
et al.303 have synthesised (2-(4-isopropyl-4-methyl)-5-oxo-2-imidazolin-2-yl)-nico-
tinic acid, a broad spectrum herbicide of the imidazolinone family and he also synthesised
its metal salt and increased stability and herbicidal activity. Tan S. and Evan R.304 have
reported imidazolinones as useful herbicides.
With a view to getting better therapeutic agent, we have synthesised novel
imidazolinones to enhance the overall activity of resulting compounds, which have been
described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1[3’-
  MERCAPTO-5’-o -CHLOROPHENY -TRIAZOL-4’-YL]-2-
  PHENYL-4-ARYLIDENE-5-OXO-IMIDAZOLES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1 [ 3 ’ - M E R C A P T O - 5 ’ -
o-CHLOROPHENYL-TRIAZOL-4’-YL]-2-PHENYL-4-ARYLIDENE-5-OXO-
IMIDAZOLES
Imidazolinone derivatives occupy a unique place in the  field of medicinal
chemistry, due to wide range of biological activities exhibited by them. Looking at the
interesting therapeutic activity of imidazolinones, it was considered worthwhile to
synthesise a series of imidazolinones of type-(VII) for obtaining biologically potent agents,
which were prepared by the condensation of 3-mercapto-4,N-amino-5-o-chlorophenyl-
1,2,4-triazole with different azlactones  in pyridine.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
Type (VII)                R = Aryl
N N
N
Cl
SH
N
N
O
R
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REACTION SCHEME
        Type - (VII)                   R=Aryl
N N
N
NH2
SH
Cl
R-CHO
N N
N
Cl
SH
N
N
O
R
+
O
NH
O
OH
CH3COONa
(CH3CO)2O
N
R
O
O
+
Pyridine
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
I R  S P E C T R A L  S T U D Y  O F  1 [ 3 ’ - M E R C A P T O - 5 ’ - o -C H L O R O PHENYL-
TRIAZOL-4’-YL]-2-PHENYL-4-(p-METHYL BENZYLIDENE)-5-OXO-IMIDA-
ZOLE
 Observed
Alkane C-H str. (asym.) 2929 2975-2950  420
-CH3 C-H str. (sym.) 2837 2880-2860   “
C-H i.p.def. (asym.) 1494 1470-1435   “
C-H o.o.p. def. (sym.) 1353 1390-1370   “
Aromatic C-H  str. 3092 3080-3030                  421
C=C str. 1571 1585-1480   “
C-H i.p. def. 1048 1125-1090   “
C-H o.o.p. def  825  835-810   “
Triazole C=N str. 1605 1640-1605 424
moiety C-N str. 1131 1220-1020 420
N-N str. 1026 1050-1010 423
C-Cl str.  695 600-800 423
Imidazolinone C=O str. 1717 1760-1655 424
C-N str. 1070 1220-1020  420
C=N str. 1605 1640-1500  424
                                                (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
25.0
50.0
75.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 468.7
 695.0
 764.7
 825.5
1026.1
1048.2
1131.2
1253.6
1304.8
1353.9
1409.91494.71571.9
1605.6
1717.5
2837.1
2929.7
3092.6
N N
N
N
N
O
Cl
SH
CH3
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R     C=O str.
      7a            4-OCH3-C6H4- 1706
7b 4-CH3-C6H4- 1717
7c 4-OH-C6H4- 1712
7d 4-Cl-C6H4- 1720
7e 4-F-C6H4- 1730
7f 3-NO2-C6H4- 1718
7g 3-Br-C6H4- 1710
7h 2-NO2-C6H4- 1712
7i 2-OH-C6H4- 1716
7j 2-Cl-C6H4- 1706
7k 3,4-(OCH3)2-C6H3- 1712
7l anthranyl- 1714
I R  S P E C T R A L  S T U D Y  O F  1 [ 3 ’ - M E R C A P T O - 5 ’ - o -C H L O R O PHENYL-
TRIAZOL-4’-YL]-2-PHENYL-4-ARYLIDENE-5-OXO-IMIDAZOLES
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 1-[3’-MERCAPTO-5’-o-CHLOROPHENYL-TRIAZOL-
4’-YL]-2-PHENYL-4-p-FLUORO BENZYLIDENE-5-OXO-IMIDAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
   In Hz
1. 7.47-7.44 2H doublet Ar-Hee’              Jef-8.6
2. 7.56-7.53 2H           multiplet         Ar-Ha,c                 -
3. 7.63-7.62 1H triplet Ar-Hb                  -
4. 8.17-8.15 2H double Ar-Hff ’   Jfe-8.4
doublet
5. 7.26 5H singlet           Phenyl-HM       -
6. 7.20 1H singlet -CHg       -
7. 8.20-8.18 1H double Ar-Hd                  -
triplet
N N
N
Cl
SH
N
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e'
M
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EXPANDED AROMATIC REGION
  MASS SPECTRUM
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1 -[ 3 ’ - M E R C A P T O - 5 ’ -
o-CHLOROPHENYL-TRIAZOL-4’-YL]-2-PHENYL-4-ARYLIDENE-5-OXO-
IMIDAZOLES
(A)  Synthesis of 3-Mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole
See [A] Part-I, Section-I (D).
(B) Synthesis of 2-Phenyl-4-(p-methoxy benzylidene)-oxazolin-5-one
A mixture of p-methoxybenzaldehyde(1.36 g,0.01M), acetic anhydride
(7.6ml, 0.075M), sodium acetate (2.0 g, 0.025M) and hippuric acid (4.4g, 0.025M)
was heated on waterbath for 4 hrs.The resulting mass was poured onto crushed ice,
filtered, washed with hot water and crystallised from ethanol. Yield 68%, m.p. 145oC,
(C16H13NO3 : Required C : 73.11; H : 4.69; N : 5.02; Found C : 73.18; H : 4.75; N :
5.09%).
TLC solvent system : Ethyl acetate : Hexane (2 : 8)
(C)  Synthesis of 1-[3’-Mercapto--5’-o-chlorophenyl-triazol-4’-yl]-2-phenyl-4-
 p-mehoxybenzylidene-5-oxo-imidazoles
A mixture of  2-phenyl-4-(p-methoxybenzylidene)-oxazolin-5-one (2.79 g, 0.01M)
and 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole (2.26g, 0.01M) in dry
pyridine (20 ml) was refluxed for 12 hrs. Resulting mass was poured on to crushed ice
and neutralised with HCl, filtered and crystallised from ethanol. Yield 52%, m.p. 114oC
(C25H18ClN5O2S : Required C: 61.54; H: 3.72; N: 14.35; Found : C: 61.77; H: 3.86;
N: 14.58%).TCL solvent system : Acetone : Benzene (3 : 7).
Similarly other imidazolin-5-ones have been prepared. The physical data are
recorded in Table No. 7.
(D) Antimicrobial activity of 1-[3’-Mercapto--5’-o-chlorophenyl-triazol-4’-yl]-2-
phenyl-4-arylidene-5-oxo-imidazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 7.
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CONCLUSION
ANTIBACTERIAL  ACTIVITY
From the experimental data it has been observed that all the compounds of
type-(VII) were active against Gram positive and Gram negative bacterial species.
It was observed that the compounds are mildly active against Gram positive
bacteria. Maximum activity was observed in compounds having R= 4-methoxyphenyl
and 4-fluorophenyl against B.coccus. The compound bearing R= 4-fluorophenyl have
highly inhibited the growth of S.aureus.
Compound with R= 4-chlorophenyl showed significant activity against
E.aerogenes. While the compound bearing R=4-hydroxyphenyl fairly inhibited the
growth of P.aeruginosa.
ANTIFUNGAL  ACTIVITY
All the compounds were active against A.niger. Maximum activity was observed
by the compounds bearing R= 4-fluorophenyl and 4-hydroxyphenyl (23mm),(21mm)
respectively.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicil l in,  ciprofloxacin,  erythromycin and antifungal activity was
compared with standard drug viz. greseofulvin.
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INTRODUCTION
Pyrimidines are among those molecules that make life possible, have been some
of the building blocks of DNA and RNA. Several analogues of pyrimidines have been
used as compounds that interfere with the synthesis and functioning of nucleic acid. e.g.
fluorouracil, which has been used in cancer treatment. There are several other important
groups of pyrimidines such as purines, uric acid, barbituric acid etc., with medicinal
uses.
With the emergence of high throughput screening in the pharmaceutical industry,
synthetic chemists have overcome the challenges of preparing large collections of
molecule, by using Multi Component Reaction strategy. The unique exploratory power
of multi-component reaction is now recognized to be extremely valuable to produce
compound libraries in a time and cost effective manner. MCRs offer significant
advantages over conventional linear type synthesis.
Multi Component Reactions occupy an outstanding position in organic and
medicinal chemistry for their high degree of atom economy, applications in combinatorial
chemistry and diversity-oriented synthesis. Such reactions leading to interesting hetero-
cyclic scaffolds are particularly useful for the creation of diverse chemical libraries of
“drug-like” molecules for biological screening.
In MCRs, three or more reactants are used to come together in a single vessel to
form a new product containing portions of each reactants. Dating back to 1893, such
MCR was done by P. Biginelli using C-H acidic carbonyl compound, aldehyde and urea-
type building blocks to assemble a multifunctionalized dihydropyrimidine scaffold. This
reaction is referred to as “Biginelli reaction”, Biginelli condensation” or as “Biginelli
dihydropyrimidine synthesis.”305-306
Since last decade, a tremendous interest has again occured for Biginelli reaction,
as it is evidenced by the fact that the product so called “dihydropyrimidine” represents
a heterocyclic system of remarkable pharmaceutical efficiency. A broad range of
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biological effects, including calcium- channel blockers307, antiviral, antitumor and
antiinflammatory308 activities has been ascribed to these partly reduced pyrimidine
derivatives. Additionally, dihydropyrimidines have been found active to transport
medication across biological membrances. Several marine alkaloids containing the
DHPMs is found in  nature and in potent HIV-gp-120-CD4 nhibitors.309
The five possible isomeric structures of dihydropyrimidines, exhibiting different
disposition of the double bonds are depicted in figure (I).
SYNTHETIC ASPECTS
There has been a considerable expansion in the numbers and types of primary
synthesis used for pyrimidines. The linking of a C-C-C fragment with an N-C-N fragment
still remains the principal synthetic method for making pyrimidines.
The simplest and the most straight forward approach for DHPMs involve one
pot condensation of an aldehyde, β-keto ester and urea or thiourea in the presence of
acid catalyst.
1. In 1893 Pietro Biginelli reported the first synthesis of dihydropyrimidines
by a simple one-pot condensation reaction of ethyl acetoacetate, benzaldehyde
and urea under strongly acidic condition.310-311
N
N
H
N
N
H
N
N
H
N
N
N
N
A B C D E
(I)
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2. Fabio Falsone et al.312 have synthesized dihydropyrimidone using polyphosphate
ester as a mild and efficient cyclocondensation/dehydration reagent.
3. Ammonium chloride-catalyzed one-pot synthesis of DHPMs under solvent-free
conditions was done by Ahmaad Shabani et al.313
4. V. R. Choudhary et al.314 have prepared DHPMs using Microwave irradiation
over Si-MCM-41 supported FeCl3 catalyst under solvent free condition.
5. An improved procedure for the synthesis of dihydropyrimidones catalysed
by lithium bromide was done by Gourhari Maiti et al.315
6. M. Adharvana Chari et al.316 have claimed Silicagel supported sodium
hydrogensulfate as a heterogenous catalyst  for high yield synthesis of 3,4-
dihydropyrimidin-2(1H)-ones.
CH3 O
EtOOC
+ Ph CHO +
NH2 NH2
O
H
+ NH
N
H
Ph
OCH3
EtOOC
(II)
R2 O
R3
O
+R1 CHO +
NH2 NH2
X
NH
N
H
R1
XR3
O
R2
NH4Cl
100 C/ 3h0
(III)X= O,S    R1=R2=R3= Alkyl, Aryl
Me O
OEt
O
+R CHO + NH2 NH2
X
NH
N
H
R
XMe
O
EtO
LiBr (cat)
CH3CN
reflux
(IV)X= O,S    R= Alkyl, Aryl
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7. Xiaoyan Han et al.317 have synthesized DHPMs using Samarium Diiodide as catalyst
under solvent free condition.
8. Highly enantioselective synthesis of DHPMs using a new chiral Ytterbium catalyst
was successfully done by Yijun Hyang et al.318
9. Ethyl 1-methyl-2-(methylthio)-6-oxo-1,6-dihydro-pyrimidine-5-carboxylate has
been investigated by M.A.Hassan et al.319 by the reaction of 5-carboethoxy-
2-thiouracil, methyl iodide with the use of tetra butylammonium bromide (PTC)
as catalyst with continuous efficient stirring for 4-6 hrs at 700C.
10. Ezzat Rafiee et al.320 described a practical and green approach towards synthesis
of dihydropyrimidinones using heteropoly acids as an efficient catalyst.
MECHANISM
Despite the importance and current interest in dihydropyrimidines of (VI), the
mechanism of the classical three-component Biginelli condensation has not been
elucidated with certainty and remains disputed.
N
NH
SH
O O
O CH3
N
NH
H3CS
O O
O CH3TBAB  ,CH3I
Stirring  4-6 h
(V)
CH3 O
O
EtO
+
O H NH2
NH2 O
NH
N
H
O
O
CH3
EtO
H+
EtOH
     (VI)
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The “carbanium ion mechanism” was proposed by Sweet and Fissekis,321 who
investigated the reaction in 1973 and suggested that an acid-catalysed aldol condensation
is the first and limiting step of the Biginelli condensation. It was proposed that under
acid catalysis benzaldehyde  and ethyl acetoacetate would react in an aldol-type fashion
to produce the corresponding aldol, which dehydrates in the presence of acid to the
resonance-stabilized carbenium ion.322(1)
Interception of cation (1) by urea or N-methylurea then produces ureides (2),
which ultimately cyclises to the Biginelli products. (3)
New drug molecules under clinical study
Recently many new molecules which are under study from phase-I to Phase-IV clinical
trials for different pharmacological action have shown that the basic characteristic of
morpholine to behave as hidden amine has attracted many medicinal chemists to
incorporate this feature in drug design. Some interesting compounds are as under.
CH3 O
EtOOC
Ph-CHO
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+
CH3 O
EtOOC
OH
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H2O
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NH2
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N
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1
138Pyrimidines.......
N
N
O
OO
O
CH3
CH3 S
N
CH3
NO2
CH3
CH3
Calcium Channel Blockers323
(VII)                (VIII)
N
NHNH
NH
N
Cl
Cl
Cl
Cl
O CH3
O
Immunosuppressants Oncolytic Drug
N
NH
S
CH3
CH3O
O
O
CH3
TNK-6123    (IX)
TNK-6123
Anti HIV Agent
Reverse Transcripase Inhibitor.
Non-nucleoside HIV-1 reverse t ran-
scriptase inhibitor
Compound was active not only against
wild-type HIV-1 strains (IC50 = 3 nM
against IIIB and NL4-3 HIV-1 strains).
THERAPEUTIC IMPORTANCE
Atwal K. S. et al.324 have described  the potent antihypertensive activity of the
modestly active (ICw = 3.2 pM) dihydropyrimidine calcium channel blocker. Victor E.
M.et al.325 synthesized 5’-triphosphates and evaluated directly as reverse transcriptase
(RT) inhibitors using both a recombinant enzyme and enzyme obtained and purified
directly from wild-type viruses. George C. et al.326 prepared dihydropyrimidine (X)
which was equipotent to nifedipine and amlodipine in vitro. In the spontaneously
hypertensive rat, dihydropyrimidine is both more potent and longer acting than nifedipine
and amlodipine. Sally Ann P. et al.327 synthesized 4,6-Bis[(R-carbamoylethyl)thio]-1-
phenylpyrazolo[3,4-d]pyrimidine (XI) which was identified as a novel adenosine A1
receptor antagonist.
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Edith Gobnitzer et al.328 have synthesized a series of 6-aryl-4-isopropyl-2-[2-
(1-phenylalkylidene)hydrazino]-1,4-dihydropyrimidine hydrochlorides and tested for their
antibacterial activity against Gram (+) and Gram (-) bacteria and also against pathogenic
yeast Candida albicans. Jayesh Modha et al.329 have prepared dihydropyrimidine
derivatives and all the compounds have been evaluated in vitro for their antimicrobial
activity against several microbes and antitubercular activity against Mycobacterium tuber
culosis H37Rv. Xiaoxiong Wei et al.330 have documented dihydropyrimidine dehydrogenase
(DPD) catabolizes endogenous pyrimidines and pyrimidine based antimetabolite drugs.
Sham M. Sondhi et al.331 have developed a number of DHPMs (XIIa-d) and carried out
their anti-inflammatory and analgesic activity. A series of [4,6-(substituted aryl)-2-thioxo-
1,2,3,4-tetrahydro-pyrimidin-5-yl]-acetic acid  have been synthesized by Sushil Kumar
and co-workers332 and their in vivo antiinflammatory activity were evaluated and compared
with standard drug Diclofenac sodium. Some compounds have shown moderate activity.
NHN
R
R3 R2
R1
S
NHN
R
R3
R2
R1
S
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S
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H R3
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Novel compounds related to 2-(cyclohexylthio)-3,4-dihydro-5-methyl-6-
(3-methylbenzyl) -4-  oxopyr imidine  (  MC 639)  have  been synthes ized   and
tested as inhibitors of human immunodeficiency virus type-1 (HIV-1) by  Antonello M.
et al.333 C. Kappe334 has synthesized novel dihydropyrimidine derivatives and
reported them as calcium channel modulators and cardiovascular agents. Adenosine has
been suggested to play an important role in asthama, possibly via activation of  A2B
Adonosine receptors on Mast cells and other Pulmonary cells. Attia  A. M. et al.335
synthesized N3-b-D-glucopyranosyl, galactopyranosyl and xylopyranosyl 6-methyl-2-
methylthiouracil and their 5-bromo derivatives  by coupling an  a-acetobromosugar with
the corresponding thiouracil. The new modified thiouridine analogues were
evaluated for their inhibitory activity against Human Immunodeficiency Virus (HIV)
replication in MT-4 cells as well as for their cytotoxicity. Jeff Zablocki and co-
workers336 have synthesized dihydropyrimidine derivatives (XIII), displayed high
affinity and good selectivity against asthama.
Barbara Schnell et al.337 have proposed enantiomerically pure dihydropyrimidine
derivatives and evaluated them as antihypertensive agents. Brian Johns and co-workers338
have discovered a novel class of pyrimidines and reported them as antiherpetic agents.
Nidhi Agarwal et al.339 have investigated pyrimidines (XIV), as antimycotic agents. All
the synthesized compounds were evaluated for their in vitro antibacterial activity, against
six pathogenic bacteria including virulent and non-virulent strain of Mycobacterium
tuberculosis. Some of the synthesized  compounds have displayed duly potent in vitro
antimycobacterial activity with MIC of 0.75 µg/mL.
N
N N
H
N
CH3
CH3
O
O N
N O
O CH3
(XIII)
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T. G. Muralidhar et al.340 have synthesized several DHPM-one analogues among
those (XV) and (XVI) give excellent selectivity (>880-fold) over α1b and α1d and also
showed good selectivity over several other recombinant human G-protein coupled receptors.
 5-Alkyl-2-thiopyrimidine nucleosides were newly synthesized by Shigeta S. et
al.341 and examined for antiviral activities against herpes simplex virus (HSV), varicella-zoster
virus VZV) and human cytomegalovirus (HCMV).
Recently, Mai A. and co-workers342 have investigated the dihydropyrimidines
which are highly active against HIV-1. Sanjay Batra et al.343 have synthesised 5-arylmethyl-
4-imino-3-aryl-3,4-dihydro-1H pyrimidin-2-ones which were tested for their antibacterial
activity. Herve Ganeste and co-workers344  synthesized substituted 1H-pyrimidin-2-
one with selective dopamine D3-receptor antagonists activity.
With an intention of preparing the compounds possessing better therapeutic
potential, we have undertaken the synthesis of dihydropyrimidine derivatives which have
been described in following sections.
N
N
H
O
H2N NO
F
O
N
Ph
CNCH3
F
H
N
N
H
MeOOC
NO
F
O
N
Ph
CH3O
CH3
F
H
 (XVI)(XV)
N
N
RS
Cl
CN
R1
(XIV) R=R1= Alkyl, Aryl
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SETION-I S Y N T H E S I S  A N D  B I O L O G I C A L S C R E E N I N G O F 4 -
ARYL-6-ISOPROPYL-5-(3’-CHLORO,4’-FLUOROPHENYL
AMINOCARBONYL)-1,2,3,4-TETRAHYDROPYRIMIDIN-2-
ONES
SECTION-II S Y N T H E S I S  A N D  B I O L O G I C A L S C R E E N I N G O F 4 -
ARYL-6-ISOPROPYL-5-(3’-CHLORO,4’-FLUOROPHENYL
AMINOCARBONYL)-1,2,3,4-TETRAHYDROPYRIMIDIN-2-
THIONES
SECTION-III S Y N T H E S I S  A N D  B I O L O G I C A L S C R E E N I N G O F 4 -
ARYL-6-ISOPROPYL-5-(3’-CHLORO,4’-FLUOROPHENYL
AMINOCARBONYL)-2-METHYLTHIO-3,4-DIHYDRO
PYRIMIDINES
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SECTION-I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-ISOPROPYL-
5-(3’-CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-1,2,3,4-TETRA
HYDROPYRIMIDIN-2-ONES
Pyrimidine derivatives possess various pharmacological and biological properties.
Here, we report the synthesis of some new pyrimidine derivatives of type (VIII). The
strategy employed for the synthesis of desired compounds involved the condensation of
N-(3-chloro,4-fluorophenyl)-3-(4-isopropyl)-3-oxopentamide, urea and aryl aldehydes.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
        Type - (VIII)                   R=Aryl
NH
N
H
O
CH3
CH3
NH
F
Cl
O R
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REACTION SCHEME
Ethylene diamine
toluene
CH3
CH3
O O
O
CH3
NH2
Cl
F+
CH3
CH3
O O
NH
Cl
F
R
O
+
NH2
O
NH2
Con. HCl  ( 2, 3 drops )
Ethanol
R
NH
N
H
CH3
CH3
O
NH
Cl
F
O
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 Observed
Alkane   C-H str. (asym.) 2958 2975-2950    420
-CH3   C-H str. (sym.) 2874 2880-2860     ,,
  C-H i.p.def. (asym.) 1456 1470-1435     ,,
  C-H o.o.p. def. (sym.) 1388 1390-1370     ,,
Isopropyl                C-H str. 1362 1385-1365                424
Aromatic   C-Hstr. 3072 3090-3030    421
  C=C str. 1513 1540-1480     ,,
Pyrimidine   C=C str. 1578 1580-1520     ,,
  C=N str. 1625 1635-1595     423
moity   C-H str. 3047 3080-3030     ,,
  C-H i.p. def. 1101 1125-1090     ,,
Amine   -NH str. 3396 3410-3380    422
  -NH def. 1625 1635-1595     “
                                               (overlaped)
Cabonyl              -C=O str. (amide) 1689 1680-1630     ,,
-C=O str. 1706 1700-1660     424
Type     Ref.        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 4-METHYLPHENYL-6-ISOPROPYL-5-
(3’-CHLORO,4’-FLUOROPHENYL)-AMINOCARBONYL-1,2,3,4-TETRAHYDRO
PYRIMIDIN-2-ONE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
 445.5
 548.7
 619.1
 634.5
 695.3
 751.2
 814.9
1101.3
1252.7
1362.0
1388.7
1456.2
1513.1
1578.0
1625.9
1689.5
1706.9
2874.7
2958.0
3047.0
3072.0
3396.4
NH
N
H
O
N
O
H
CH3
CH3
CH3
Cl
F
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R C=O str.(amide)                      C=O str.(pyri.)
      8a            C6H5-                                  1661  1706
8b 4-OCH3-C6H4-                   1671 1717
8c 4-CH3-C6H4-                      1689 1706
8d 4-Cl-C6H4-                         1677 1720
8e 4-F-C6H4-                          1687 1730
8f 4-OH-C6H4-                       1669 1725
8g 4-NO2-C6H4-                     1676 1718
8h 3-OH-C6H4-                       1665 1710
8i 3-NO2-C6H4-                     1674 1712
8j 2-OH-C6H4-                       1669 1716
8k 2-NO2-C6H4-                     1678 1706
8l 2-Cl-C6H4-                         1682 1712
IR  SPECTRAL STUDY OF  4-ARYL-6-ISOPROPYL-5-(3’-CHLORO,4’-
FLUOROPHENYL)-AMINOCARBONYL-1,2,3,4-TETRAHYDRO PYRIMIDIN-2-
ONES
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-1 1.56 3H singlet C-CH3(e)
2 1.73 3H singlet C-CH3(f) -
3 5.15 1H singlet C-CH(g) -
4 5.46 1H singlet Pyrimidine-Hj -
5 7.10-7.29 1H triplet Ar-Hc -
6 7.30-7.33 2H doublet Ar-Hkk’  Jkl-9.2
7. 7.49-7.52 2H doublet Ar-Hll’   Jkl-10.0
8. 7.75-7.76 1H doublet Ar-Ha   Jac-4.2
9. 7.84-7.86 1H doublet Ar-Hb   Jbc-8.0
10. 8.05 1H singlet Pyrimidine-NHi -
11. 9.33 1H singlet Pyrimidine-NHh -
12. 9.50 1H singlet Amide-NHd -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 4-CHLOROPHENYL-6-ISOPROPYL-5-
( 3 ’ - C H L O R O , 4 ’ - F L U O R O P H E N Y L ) - A M I N O C A R B O N Y L - 1 , 2 , 3 , 4 -
TETRAHYDRO PYRIMIDIN-2-ONE
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
NH
N
H
O
N
O
H
CH3
CH3
Cl
F
Cl
a
b
c
d
e
f
g
h
i
j
kk'
ll'
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EXPANDED AROMATIC REGION
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H
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3
CH3
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b
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g
h
i
j
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MASS SPECTRUM
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-ISOPROPYL-
5-(3’-CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-1,2,3,4-TETRA
HYDROPYRIMIDIN-2-ONES
[A] Synthesis of N-(3-chloro,4-fluorophenyl)-3-(4-isopropyl)-3-oxopentamide
 2-Methyl pentanoat 3-one (0.01m, 1.44ml) and 3-chloro,4-fluoro aniline (0.01m, 1.45gm)
in 25ml toluene was heated  for 12 hrs using ethylenediamine (1 ml) as catalyst. Methanol
was removed using Dean & Stark azeotropic assembly. The mixture was cooled to room
temperature and then washed with sodium bisulphite solution. The layers were settled
down, organic layer was seperated. It was further washed with water and layers were
seperated.  Excess of solvent was distilled out and the product was isolated, m.p.1540C,
yield 62%.
TLC System : Ethyl acetate : Hexane (2 : 3)
[B] Synthesis of 4-Phenyl-6-isopropyl-5-(3’-chloro,4’-fluorophenyl aminocarbonyl)-
1,2,3,4-tetrahydropyrimidin-2-one
A mixture of  N-(3-chloro,4-fluorophenyl)-3-(4-isopropyl)-3-oxopentamide
(2.57gm, 0.01M), urea (0.60gm, 0.01) and benzaldehyde (1.06gm, 0.01) in 15ml of
ethanol containing few drops of concentrated hydrochloric acid was refluxed for 4-5
hrs. The solution was allowed to stand for 12 hrs at room temperature and the resulting
solid mass seperated was filtered and crystralized with dioxane, m.p. 1880C, yield  44%.
C20H19ClFN3O2  required; C, 61.94%; H, 4.94%;  N, 10.83%;  found; C, 62.15%;
H, 5.19%;  N, 10.98%.
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly other 4-(aryl)-6-isopropyl-5-(3’-chloro,4’-fluorophenyl amino
carbonyl)-1,2,3,4-tetrahydropyrimidin-2-one derivatives were synthesised. The physical
data are recorded in Table No. 8.
[C] Antimicrobial activity of 4-Aryl-6-isopropyl-5-(3’-chloro,4’-fluorophenyl-
aminocarbonyl)-1,2,3,4-tetrahydro pyrimidin-2-ones
Antimicrobial testing was carried out as described in [A] part-1, section-I (F).
The zone of inhibition of test solutions are recorded in graphical chart No.8.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all the compounds were
moderately active against Gram positive & Gram negative bacterial strains.
In case of Gram positive bacterial strain, maximum activity was observed in
compounds bearing R =4-nitrophenyl and 4-chlorophenyl which fairly inhibit the growth
of B. coccus. Almost all the compounds have least activity against S. aureus, while the
compounds having R= 4-hydroxyphenyl and 4-chlorophenyl displayed significant activity.
In  case  of  Gram negat ive  bac ter ia l  s t ra in ,  compounds  bear ing
R=4-methoxyphenyl, 2-nitrophenyl and 3-nitrophenyl  have shown maximum activity
against E.aerogenes and R=4-chlorophenyl, 4-nitrophenyl against P.aeruginosa.
ANTIFUNGAL ACTIVITY
 All the compound have shown mild activity against A. niger, while the compounds
having R=4-methoxylphenyl and 4-nitrophenyl fairly inhibit the growth of
A. niger and the zone of inhibition is 19mm and 23mm respectively.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz. greseofulvin.
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SECTION-II
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-ISOPROPYL-
5-(3’-CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-1,2,3,4-TETRA
HYDROPYRIMIDIN-2-THIONES
 Thiopyrimidine derivatives represent one of the most active class of compounds
having wide spectrum of biological activities. These valid observations led us to synthesise
pyrimidine thiones of type-(IX) by the condensation of  N-(3-chloro,4-fluorophenyl)-3-
(4-isopropyl)-3-oxopentamide, thiourea and aryl aldehydes.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
        Type - (IX)                   R=Aryl
NH
N
H
S
CH3
CH3
NH
F
Cl
O R
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REACTION SCHEME
Ethylene diamine
toluene
CH3
CH3
O O
O
CH3
NH2
Cl
F+
CH3
CH3
O O
NH
Cl
F
R
O
+
NH2
S
NH2
Con. HCl  ( 2, 3 drops )
R
NH
N
H
CH3
CH3
O
NH
Cl
F
S
Ethanol
        Type - (IX)                           R=Aryl
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 Observed
Alkane C-H str. (asym.) 2949 2975-2950    420
-CH3 C-H str. (sym.) 2852 2880-2860     ,,
C-H def. (asym.) 1487 1470-1435     ,,
C-H def. (sym.) 1431 1390-1370     ,,
Isopropyl -C-H str. 1379 1385-1365     424
Aromatic C-H  str. 3024 3090-3030     421
C=C str. 1533 1540-1480     ,,
C-H i.p. (def) 1083 1125-1090     ,,
C-H o.o.p. (def) 817 835-810     ,,
Pyrimidine C=C str. 1573 1580-1520     422
moity C-H str. 2923 2975-2950     ,,
C-H i.p. def. 1049 1125-1090     ,,
Amine -NH str. 3427 3410-3380     423
-NH def. 1610 1635-1595     424
  Amide -C=O str. 1699 1690-1660            ,,
-C=S str. 1205 1300-1110     ,,
 Halide -C-Cl str. 729 700-750     423
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 4-(p-METHYLPHENYL)-6-ISOPROPYL-5-
(3’-CHLORO,4’-FLUOROPHENYL)-AMINOCARBONYL1,2,3,4-TETRAHYDRO
PYRIMIDIN-2-THIONE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 466.7
 524.6
 549.7
 607.5
 628.8
 669.3
 711.7
 729.0
 763.8
 794.6
 817.8
 883.3
 941.2
 962.4
1022.2
1049.2
1083.9
1128.3
1205.4
1267.1
1284.5
1338.5
1379.0
1431.1
1487.0
1508.2
1533.3157 .7
1610.5
1633.6
1699.2
2852.5
2923.9
2949.0
3024.2
3427.3
NH
N
H
O
N
S
H
CH3
CH3
Cl
F
CH3
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R     C=O str.(amide)
      9a            C6H5- 1668
9b 4-OCH3-C6H4- 1687
9c 4-CH3-C6H4- 1699
9d 4-Cl-C6H4- 1691
9e 4-F-C6H4- 1697
9f 4-OH-C6H4- 1676
9g 4-NO2-C6H4- 1684
9h 3-OH-C6H4- 1681
9i 3-NO2-C6H4- 1679
9j 2-OH-C6H4- 1687
9k 2-NO2-C6H4- 1691
9l 2-Cl-C6H4- 1695
IR SPECTRAL STUDIES OF 4-ARYL-6-ISOPROPYL-5-(3’-CHLORO,4’-
FLUOROPHENYL)-AMINOCARBONYL1,2,3,4-TETRAHYDRO PYRIMIDIN-2-
THIONE
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NMR SPECTRAL STUDIES OF 4-(p-CHLOROPHENYL)-6-ISOPROPYL-5-
(3’-CHLORO,4’-FLUOROPHENYL)-AMINOCARBONYL-1,2,3,4-TETRAHYDRO
PYRIMIDIN-2-THIONE
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
NH
N
H
O
N
S
H
CH3
CH3
Cl
F
Cl
a
b
c
d
e
f
g
h
i
j
kk'
ll'
1 1.54 3H singlet C-CH3(e)      -
2 1.76 3H singlet C-CH3(f)      -
3 3.82 1H singlet C-CH(g)      -
4 5.17 1H singlet         Pyrimidine-Hj      -
5 7.07-7.09 1H doublet Ar-Hb Jbc-8.8
6 7.28-7.30 2H doublet Ar-Hkk’ Jkl-8.4
7 7.14-7.17 2H doublet Ar-Hll’ Jlk-8.6
8 7.51-7.52 1H doublet Ar-Ha Jac-3.6
9 7.80-7.83 1H double Ar-Hc      -
doublet
10 8.52 1H singlet         Pyrimidine-Hi       -
11 8.85 1H singlet         Pyrimidine-Hh       -
12 9.25 1H singlet Amide-Hd       -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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EXPANDED AROMATIC REGION
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160Pyrimidines.......
C
H
3
N
H
N H
S
O
N
H
C
l
C
l
F
C
H
3
m
/z
 =
 4
38
C
H
3
N H
N
H
S
O
N
H
F
C
H
3
m
/z
 =
 2
93
N
H
N
H
S
O
N
H
F
C
H
3
m
/z
 =
 2
65
N
H
N
H
S
O
N
H
F
m
/z
 =
 2
51
N
H
N
H
S
O
N
H
m
/z
 =
 2
33
N
H
N
H
O
N
H
m
/z
 =
 2
05
N
H
N
H
N
H
m
/z
 =
 1
91
C
H
2
N
H
F
C
l m
/z
 =
 1
71
C
H
3
N
H
C
l
m
/z
 =
 1
55
C
H
3
N
H
C
l
m
/z
 =
 1
40
C
H
3
N
H
F
m
/z
 =
 1
25
N
H
2
F
m
/z
 =
 1
11
F
C
H
2
C
H
3
m
/z
 =
 6
8
m
/z
 =
 9
6
+ o
+ o
+ o
+ o
+ o
+ o
+ o + o
+ o
+ o
+ o
+ o+ o
+ o
161Pyrimidines.......
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-ISOPROPYL-
5-(3’-CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-1,2,3,4-TETRA
HYDROPYRIMIDIN-2-THIONES
[A] Synthesis of N-(3-Chloro,4-fluorophenyl)-3-(4-isopropyl)-3-oxopentamide
See [B] Part-I,Section-I (A)
[B] Synthesis of 4-Phenyl-6-isopropyl-5-(3’-chloro,4’-fluorophenyl amino carbonyl)-
1,2,3,4-tetrahydro pyrimidin-2-thione
A mixture of N-(3-chloro,4-fluorophenyl)-3-(4-isopropyl)-3-oxopentamide
(2.57gm, 0.01), thiourea (0.76gm, 0.01) and benzaldehyde (1.06gm, 0.01) in 15ml of
ethanol containing few drops of concentrated hydrochloric acid was refluxed for 4-5
hrs. The solution was allowed to stand for 12 hrs. at room temperature and the resulting
solid mass seperated was filtered and crystralized from dioxane.m.p. 1320C, yield 47%,
C20H19ClFN3OS  required; C, 57.47%; H, 4.74%;  N, 10.38%;  found; C, 57.68%;
H, 4.86%;  N, 10.50%.
TLC System : Ethyl acetate : Hexane (3 : 7)
Similarly other 4-aryl-6-isopropyl-5-(3’-chloro,4’-fluorophenyl amino
carbonyl)-1,2,3,4-tetrahydro pyrimidin-2-thione derivatives were synthesised. The
physical data are recorded in Table No. 9.
[C] Antimicrobial activity of 4-Aryl-6-isopropyl-5-(3’-chloro,4’-fluorophenyl
aminocarbonyl)-1,2,3,4-tetrahydro pyrimidin-2-thiones
Antimicrobial testing was carried out as described in [A] part-1, section-I (F).
The zone of inhibition of test solutions are recorded in graphical chart No. 9.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data, it has been concluded that the compounds
bearing R=4-chlorophenyl and 4-nitrophenyl have displayed considerable activity against
B. coccus. The compound having R= 4-nitrophenyl have shown maximum activity against
S. aureus.
In case of Gram negative bacterial strain,the significant activity was displayed by
the compound bearing R=4-nitrophenyl against E.aerogenes and R= 4-methylphenyl
against P.aeruginosa.
ANTIFUNGAL ACTIVITY
 All the compound have shown mild activity against  A. niger, while the
compounds having R=4-chlorohenyl and 4-hydroxyphenyl displayed better activity.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin &antifungal
activity was compared with standard drug viz. greseofulvin.
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SECTION-III
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-ISOPROPYL-
5-(3’-CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-2-METHYLTHIO-
3,4-DIHYDROPYRIMIDINES
Many thiomethylpyrimidine derivatives occupy a unique place in the field of
medicinal chemistry due to wide range of biological activities exhibited by them. In view
of these fact, it was contemplated to synthesise thiomethyl pyrimidines derivatives of  type
(X) by the condensation of N-(3-chloro,4-fluorophenyl)-3-(4-isopropyl)-3-oxopentamide,
methyl imidothiocarbamate and different aryl aldehydes.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
        Type - (X)                   R=Aryl
N
N
H
S
CH3
CH3
NH
F
Cl
O R
CH3
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REACTION SCHEME
Morpholine, Toluene
gl.acetic acid
+
CH3
CH3
O O
NH
Cl
F
R
O
+ NH2
S
NH
CH3
Toluene
R
N
N
H
CH3
CH3
O
NH
Cl
F
S
CH3
NaHCO3
CH3
CH3
OO
NH
Cl
F
R
        Type - (X)                   R=Aryl
167Pyrimidines.......
IR SPECTRAL STUDIES OF 4-(p-CHLOROPHENYL)-6-ISOPROPYL-5-
(3’-CHLORO,4’-FLUOROPHENYL)-AMINOCARBONYL-2-METHYLTHIO-3,4-
DIHYDROPYRIMIDINE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2921 2975-2950    420
-CH3 C-H str. (sym.) 2877 2880-2860     ,,
C-H def. (asym.) 1476 1470-1435     ,,
C-H def. (sym.) 1396 1390-1370     ,,
Isopropyl C-H str. 1371 1385-1365    424
Aromatic C-H  str. 3071 3090-3030    421
C=C str. 1518 1540-1480     ,,
C-H i.p. (def) 1094 1125-1090     ,,
C-H o.o.p. (def) 800 835-810     ,,
Pyrimidine C=C str. 1594 1580-1520     422
moity C-H str. 3119 3080-3030     ,,
C-H i.p. def. 1056 1125-1090     ,,
-NH str. 3414 3410-3380     423
-NH def. 1618 1635-1595     ,,
 Amide            -C=O str. 1656 1690-1660            ,,
  Halide C-Cl str. 716 750-700     424
C-S-C str. 691 700-600     “
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode N
N
H
O
N
S
H
CH3
CH3
Cl
F
Cl
CH3
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R     C=O str. (amide)
      10a            C6H5- 1660
10b 4-OCH3-C6H4- 1669
10c 4-CH3-C6H4- 1666
10d 4-Cl-C6H4- 1656
10e 4-F-C6H4- 1681
10f 4-OH-C6H4- 1674
10g 4-NO2-C6H4- 1677
10h 3-OH-C6H4- 1677
10i 3-NO2-C6H4- 1679
10j 2-OH-C6H4- 1683
10k 2-NO2-C6H4- 1671
10l 2-Cl-C6H4- 1682
IR SPECTRAL STUDIES OF 4-ARYL-6-ISOPROPYL-5-(3’-CHLORO,4’-
F L U O R O P H E N Y L ) - A M I N O C A R B O N Y L - 2 - M E T H Y LT H I O - 3 , 4 -
DIHYDROPYRIMIDINE
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NMR SPECTRAL STUDIES OF 4-(p-CHLOROPHENYL)-6-ISOPROPYL-5-
(3’-CHLORO,4’-FLUOROPHENYL)-AMINOCARBONYL-2-METHYLTHIO-3,4-
DIHYDROPYRIMIDINE
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
N
N
H
O
N
S
H
CH3
CH3
Cl
F
CH3
Cl
a
b
c
d
e
f
g
h
i
j
kk'
ll'
1 1.56 3H singlet C-CH3(e)      -
2 1.92 3H singlet C-CH3(f)      -
3 2.56 3H singlet S-CH3i      -
4 4.04 1H singlet C-CH(g)      -
5 5.18 1H singlet         Pyrimidine-Hj      -
6 7.05-7.10 1H miltiplet Ar-H b+c      -
7 7.20-7.22 2H doublet Ar-Hll’ Jlk-8.0
8 7.27-7.29 2H miltiplet Ar-Hkk’+a Jkl-8.36
9 7.41 1H singlet         Pyrimidine-Hh       -
10 7.87 1H singlet Amide-Hd       -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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EXPANDED AROMATIC REGION
N
N
H
O
N
S
H
CH3
CH3
Cl
F
Cl
CH3
a
b
c
d
e
f
g
h
i
j
kk'
ll'
MASS SPECTRUM
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-6-ISOPROPYL-
5-(3’-CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-2-METHYLTHIO-
3,4-DIHYDROPYRIMIDINES
[A] Synthesis of N-(3-Chloro,4-fluorophenyl)-3-(4-isopropyl)-3-oxopentamide
See [B] part-1,section-I(A)
[B] Synthesis of N-(3-Chloro,4-fluorophenyl)-2-(4-methoxybenzylidine)-3-
(4-isopropyl)-3-oxopentamide
 A mixture of  N-(3-chloro,4-fluorophenyl)-3-(4-isopropyl)-3-oxopentamide
(2.57gm, 0.01) and anisaldehyde (1.36gm, 0.01) in 25ml of toluene was heated for
14-16 hrs. using  morpholine (1 ml) as catalyst. Water was removed azeotropically
using Dean & Stark assembly. The mixture was cooled to room temperature and sodium
bisulphite treatment was given. Then, it was stirred  for 15 mins., settled down  for 20
mins. The layers were seperated and organic layer was washed with sodium bisulphite
solution,  further stirred for 15 mins. The layers were settled down, organic layer was
seperated out. Excess of the solvent was distilled out and product was isolated, crystalized
from DMF, m.p.1920C, yield 54%, (C20H19ClFNO3) required; C, 63.92%; H, 5.10%;
N, 3.73%;  found; C, 64.09%; H, 5.40%;  N, 3.90%.
TLC System : Ethyl acetate : Hexane (2 : 3).
[C] Synthesis of 4-Methoxyphenyl-6-isopropyl-5-(3’-chloro,4’-fluorophenyl-
aminocarbonyl)-2-methylthio-3,4-dihydro pyrimidine
The sulphate salt of methyl imidothio carbamate (0.015m, 2.80gm) was dissolved
in DMSO, NaHCO3 (2gm) was added  and stirred for 15 mins. Then N-(3-chloro,4-
f luorophenyl)-2-(4-methoxybenzylidine)-3-(4-isopropyl)-3-oxopentamide
(0.01m, 3.75gm) was added and the mixture was heated at 75-800C for 8 hrs. It was
then cooled to room temperature and dumped into water and toluene. Then organic
layer was seperated, 5 ml of NH3  solution  and 20 ml of water was added. The mixture
was further stirred for 10 mins, organic layer was seperated out and washed  with water.
HCl was added till acidic pH. The material was filtered and further washed with toluene
and water.
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Ammonia solution was added till 8-9 pH. Organic layer was seperated. Excess
of solvent was distilled out. The product was isolated and crystalized from DMF, m.p.
1840C, yield 48%, (C22H23ClFN3O2S)  required; C, 58.99%; H, 5.18%; N, 9.35%;  found;
C, 59.06%; H, 5.31%;  N, 9.54%.
TLC System : Ethyl acetate : Hexane (4 : 6)
Similarly other 4-aryl-6-isopropyl-5-(3’-chloro,4’-fluorophenyl-amino carbonyl)-
2-methylthio-3,4-dihydro pyrimidine derivatives were synthesised. The physical data
are recorded in Table No.10.
[D] Antimicrobial activity of 4-Aryl-6-isopropyl-5-(3’-chloro,4’-fluorophenyl-
aminocarbonyl)-2-methylthio-3,4-dihydro pyrimidines
Antimicrobial testing was carried out as described in [A] part-1, section-I (F).
The zone of inhibition of test solutions are recorded in graphical chart No.10
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all the compounds were
moderately active against Gram positive & Gram negative bacterial strains. In case of
Gram positive bacterial strain maximum activity was observed. Compound bearing R=4-chloro
phenyl fairly inhibit the growth of B. coccus. Almost all the compounds have least active
against S. aureus, while the compound having 4-nitrophenyl shows significant activity.
In case of Gram negative bacterial strain, compounds bearing R=4-chlorophenyl
and 4-nitrophenyl  have shown maximum activity against E.aerogenes and R=4-methoxy
phenyl and 4-fluorophenyl give the zone of inhibition respectively (20mm) and (22mm)
against P.aeruginosa.
ANTIFUNGAL ACTIVITY
 All the compound have shown mild activity against A.niger, while the compounds
having R=4-fluorophenyl and 4-nitrophenyl shown significant activity.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz. greseofulvin.
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INTRODUCTION
It is well known that pyrimidine and fused heterocyclic pyrimidine derivatives are
of great biological interest, especially as they exhibit various pharmacological activities.
As a result pyrimidine has been subjected to a large variety of structural modifications in
order to synthesise derivatives with better biological potency. Thiazolo-pyrimidine is
one of the motif, that is concerned with.
The literature on thiazolo-pyrimidines has been reviewed345-347. Different types
of thiazolopyrimidine are shown below.
The importance of the thiazolo-pyrimidine ring system as an antipurine and hence
its importance  as an anticancer agent has been previously recognized.348 It has wide
antimicrobial activities including bacteriostatic, antiprotozoal and antischistosomal.349-351
As well, several thiazolo-pyrimidine derivatives have been found to possess molluscicidal
properties.352
SYNTHETIC ASPECTS
Several methods have been reported in the literatures for the preparation of
thiazolo-pyrimidine. Some procedures have been described as under.
1. A. Mobinikhaledi et al.353 have synthesized thiazolo-pyrimidines using
thiopyrimidines and 1,2-dibromoethane in DMF.
N
N S
NN
S
N
N
S
NN
S
1
2
345
6
7
8
1
2 2
2
1
1
345
6
7
8
345
6
7
8
345
6
7
8
        3H-Thiazolo[3,4-a]pyrimidine        3H-Thiazolo[3,4-c]pyrimidine
        5H-Thiazolo[3,2-a]pyrimidine         5H-Thiazolo[3,2-c]pyrimidine
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NH
N
H
CH3
EtOOC
S
R
N
N
H
CH3
EtOOC
S
R
+ Br CH2 CH2 Br DMFReflux
       R=alkyl
2. A simple and easy synthesis of some thiazolo-pyrimidines in high yield has been
developed using microwave assisted cyclocondensation reaction of thio
pyrimidines, chloroacetic acid, corresponding aldehydes and sodium acetate
by N. Foroughifar et al.354
3. M. A. Jacobson et al.355 have prepared thiazolo-pyrimidine derivatives by azole
approach using 2-amino thiazole, ethyl cyanoacetate in sodium ethoxide using
PPA or acetic acid.
4. T. I. El-Emary et al.356 have synthesized thiazolopyrimidine derivatives from
amino- thiazole derivatives using benzoylisothiocyanate and KOH in ethanol at
400 C with stirring.
NH
N
H
Ar
CH3
EtOOC
S
N
NCH3
EtOOC
S
O
Ar'
Ar
Cl CH2 COOH
AcONa, MW
Ar'-CHO
       Ar=Ar’=Aryl
N
SNH2
NC CH2 COOEt
EtONa, PPA
N
N S
NH
O
R1
R
       R=R1=H
      (I)
      (II)
      (III)
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PhCONCSN
S
MeS
NH2
COOEt
KOH
NH
N
N
S
MeS
O
R
       R=CH2CN,SH
5. The Hantzsch type condensation of dihydropyrimidines with a substituted 2-
bromophenylacetaldehyde led to the thiazolopyrimdines was documented by
G.. Adam et al.357
THERAPEUTIC IMPORTANCE
Thiazolo-pyrimidines and and its derivatives are actively involved in
pharmacologically useful entities. Some compounds have proved to be successful
chemotherapeutic agent which are discribed as under.
1. Anticonvulsant358
2. CNS depressant359
3. Anthelmintics360
4. Antidiabetic361
5. Antifolatic362
6. Antiinflammatory363
7. Anticancer364
8. Antibacterial365
9. Antihypertensive366
10. Antiviral367
NH
N
H
R1
S
O
R2
R3
+ HC Br
CHO
R4
Me CN
N
N
R1
S
O
R2
R4
R3
       R1=Me, Et, iPr
       R2=OEt, O(CH2)2NMe2
                   R3=Me, OMe, OEt, F, Cl
                   R4=Cl, diCl
      (IV)
      (V)
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A series of alkyl and alkenyl guanine analouges (VI) containing a thiazolo[4,5-d]
pyrimidine ring system were prepared by Arthur F. Lewis368. In preliminary antiviral
efficasy evaluation against both human cytomegalovirus (HCMV) and herpes simplex
virus most of the compounds found highly active as compared to standard drug. H.Furrer
et al.369 have documented series of thiazolo[3,2-c]pyrimidines. Results from in vivo
evaluations in rats have shown that many of these compounds produce a pronounced
increase of HDL cholesterol and marked decrease of LDL and VLDL cholesterol. Novel
2-benzylidin-7-methyl-3-oxo-5-(substituted phenyl)-2,3-dihydro-5H-thiazolo[3,2-a]
pyrimidines have been synthesized by Birsen Tozkoparan and co-workers370. The
compounds were tested for their antiinflammatory activities. The results revealed that
most of the compounds exerted moderate antiinflammatory activity at the 100mg/kg
dose level compared with indomethacin.
Mark Hellberg  and co-workers371 have discovered a series of mesoionic
thiazolopyrimidines and related analogues, which were examined as inhibitors of human
platelet aggregation. Appropriately substituted compounds were found to fully inhibit
platelet  aggregation. Sh.H.Abdel-Hafez et  al .372 have synthesised novel
thiazolopyrimidine derivatives and studied their antifungal activity. Most of the compounds
showed more fungitoxicity activity. A.Mobinikhaledi et al.373 have discovered new
thiazolopyrimidines and reported them as antibacterial agents. Hammam Abou and
co-workers374 have prepared some novel thiazolopyrimidines and examined their
aticancer activity.
Recently, Soad A.M.El-Hawash et al.375 have documented substituted 2-thioxo-
2,3-dihydro 6H-thiazolo[4,5-d]pyrimidines and all the compounds were evaluated for
N
NH
S
N
CH3
NH2
OO
      (VI)
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their anticancer activity using the USA-NCI in vitro screening programme. Among the
tested compounds some of the compounds exhibited high value of percent tumor growth
inhibition at concentration of 10-5 to 10-7 M in all cancer cell line. In addition, nine
compounds were investigated for their in vitro effect on the replication of hepatities-C-
virus (HCV) in HepG2 ,hepatocellular Cell line infected with the virus using the reverse
transcription polymerase chain reaction technique. Hayam H. Sayed etal.376 have
prepared thiazolopyrimidine derivatives (VII) and tested for their antimicrobial activity.
Evaluation of the new compounds established that some of the compounds were slightly
active against the tested miccroorganisms.While all the compounds revealed antifungal
activity more effective than the other tested compounds and the reference drug. Andrew
Baxter et al.377 have synthesised thiazolopyrimidine derivatives (VIII) and screened
for their CXCR2 receptor antagonist activity.
The development of efficient and selective synthesis by structural modification of
thiazolopyrimidines have attracted increasing attention over the last several years, because
they often bring about unique physiological properties. These findings encouraged us to
search some novel thiazolopyrimidine derivatives.
SECTION-I : SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-ARYL-7-
ISOPROPYL-6-(3’-CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-
2,3-DIHYDRO-THIAZOLO[2,3-b]PYRIMIDINES
S
N N
N
S
NH
CH3
CH3
OH NH2
F
F
N
N S
O
NCl-H4C6-HC=N
C6H4-Cl
Cl-H4C6-HC=N
O
CH3
      (VII)
      (VIII)
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SECTION-I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-ARYL-7-ISOPROPYL-
6-(3’-CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-2,3-DIHYDRO-
THIAZOLO[2,3-b]PYRIMIDINES
 With a view to getting better therapeutic agents of thiazolopyrimidine hetero-
cycles and to further assess the potential of such a class of compounds thiazolopyrimidine
derivatives of type-(XI) have been synthesized by the condensation of 4-aryl-6-isopropyl-5-
3’-chloro,4’-fluorophenyl aminocarbonyl -1,2,3,4-tetrahydropyrimidin-2-thiones, 1,2-
dibromoethane in DMF.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
N
N
R
CH3
CH3
S
NH
O
Cl
F
Type-(XI)           R=Aryl
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CH3
CH3
O O
NH
Cl
F
Cl
O+
NH2
S
NH2
Con. HCl  ( 2 , 3 drops )
NH
N
H
Cl
CH3
CH3
O
NH
Cl
F
S
Ethanol
+
Br
Br
DMF
R
N
N
CH3
CH3
O
NH
Cl
F
S
REACTION SCHEME
        Type - (XI)                   R=Aryl
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 Observed
Alkane C-H str. (asym.) 2937 2975-2950    420
-CH3 C-H str. (sym.) 2854 2880-2860    ,,
C-H def. (asym.) 1488 1470-1435    ,,
C-H def. (sym.) 1442 1390-1370    ,,
Isopropyl -C-H str. 1383 1385-1365    424
Thiazolo ring -CH2str. 1277 1270-1230    421
Aromatic C-H  str. 3033 3090-3030    ,,
C=C str. 1530 1540-1480    ,,
C-H i.p. (def) 1061 1125-1090    422
C-H o.o.p. (def) 826 835-810    ,,
Pyrimidine C=C str. 1598 1580-1520    ,,
moity C-H str. 3048 3080-3030    ,,
C-H i.p. def. 1061 1125-1090    ,,
Amine -NH str. 3358 3410-3380    423
-NH def. 1598 1635-1595    ,,
                                              (overlapped)
  Amide -C=O str. 1675 1690-1660                ,,
-C=S str. 1170 1300-110    424
 Halide -C-Cl str. 693 700-750    ,,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 5 - (p-METHYL)- 7 - I S O P R O P Y L - 6 - (3’-
CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-2,3-DIHYDRO-
THIAZOLO[2,3-b]PYRIMIDINE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/t
 542.0
 601.7
 634.5
 693.4
 757.0
 826.4
1061.7
1170.7
1203.5
1277.8
1377.1
1383.8
1411.8
1442.7
1488.9
1530.4
1598.9
1675.1
2854.5
2937.4
3033.8
3048.3
3202.6
3358.8
N
N
O
N
H
CH3
CH3
Cl
F
CH3
S
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R     C=O str.
      11a            C6H5- 1669
11b 4-OCH3-C6H4- 1679
11c 4-CH3-C6H4- 1675
11d 4-Cl-C6H4- 1684
11e 4-F-C6H4- 1693
11f 4-OH-C6H4- 1671
11g 4-NO2-C6H4- 1682
11h 3-OH-C6H4- 1677
11i 3-NO2-C6H4- 1685
11j 2-OH-C6H4- 1678
11k 2-NO2-C6H4- 1688
11l 2-Cl-C6H4- 1693
IR SPECTRAL STUDIES OF 5 - ARYL- 7 - I S O P R O P Y L - 6 - (3’-CHLORO,4’-
FLUOROPHENYLAMINOCARBONYL)-2,3-DIHYDRO-THIAZOLO[2,3-
b]PYRIMIDINE
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1 1.40 3H singlet C-CH3(e)      -
2 1.65 3H singlet C-CH3(f)      -
3 3.69 1H singlet C-CH(g)      -
4 3.78 3H singlet Ar-OCH3      -
5 5.16 1H singlet        Pyrimidine-Hj      -
6 3.15 1H singlet         Thiazolo-Hia       -
7 3.45 1H singlet         Thiazolo-Hib       -
8 3.95 1H singlet         Thiazolo-Hha       -
9 4.20 1H singlet         Thiazolo-Hhb       -
10 6.77-6.79 2H doublet Ar-Hkk’ Jkl-6.76
11 7.11-7.13 2H doublet Ar-Hll’ Jlk-6.84
12 7.31-7.33 1H doublet Ar-Hb Jbc-8.76
13 7.48-7.51 1H double Ar-Hc      -
doublet
14 7.902-7.908 1H doublet Ar-Ha Jac-2.40
15 9.72 1H singlet Amide-Hd       -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 5 - (p-METHOXY)- 7 - I S O P R O P Y L - 6 - (3’-
CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-2,3-DIHYDRO-
THIAZOLO[2,3-b]PYRIMIDINE
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
N
N
O
N
H
CH3
CH3
Cl
F
OCH3
S
a
b
c
d
e
f
g
j
kk'
ll'
h
i
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EXPANDED AROMATIC REGION
N
N
O
N
H
CH3
CH3
Cl
F
OCH3
S
a
b
c
d
e
f
g
j
kk'
ll'
h
i
N
N
CH3
CH3
S
NH
O
Cl
F
Cl
MASS SPECTRUM
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5 - ARYL- 7 - I S O P R O -
P Y L - 6 - (3’-CHLORO,4’-FLUOROPHENYLAMINOCARBONYL)-2,3-
DIHYDRO-THIAZOLO[2,3-b]PYRIMIDINES
[A] Synthesis of N-(3-chloro,4-fluorophenyl)-3-(4-isopropyl)-3-oxopentamide
See [B] Part-I,Section-I (A)
[B] Synthesis of 4-Phenyl-6-isopropyl-5-(3’-chloro,4’-fluorophenyl amino carbonyl)-
1,2,3,4-tetrahydropyrimidine-2-thione
A mixture of N-(3-chloro,4-flourophenyl)-3-(4-isopropyl)-3-oxopentamide
(2.57gm, 0.01M), thiourea (0.76gm, 0.01M) and benzaldehyde (1.06gm, 0.01M) in
15ml of ethanol containing few drops of concentrated hydrochloric acid was refluxed
for 4-5 hrs. The solution was allowed to stand for 12 hrs. at room temperature and the
resulting solid mass seperated was filtered and crystalized from dioxane, m.p. 1320C,
yield 47%, (C20H19ClFN3OS)  required; C, (57.47%); H, (4.74%);  N, (10.38%);
found; C, (57.68%); H, (4.86%);  N, (10.50%).
TLC System : Ethyl acetate : Hexane (3 : 2)
[C] Synthesis of 5-Phenyl-7-isopropyl-6-(3’-chloro,4’-fluorophenyl aminocarbonyl)-
2,3-dihydro-thiazolo[2,3-b]pyrimidine
1,2-Dibromo ethane (1.87ml, 0.01M) was added to a boiling solution of 4-Phenyl-6-
isopropyl-5-(3’-chloro,4’-fluorophenyl amino carbonyl)-1,2,3,4-tetrahydro pyrimidine-2-
thione (4.29gm, 0.01M) in DMF (12ml), then refluxed for 4 hrs. The reaction mixture
was cooled and solid thus seperated was filtered. It was crystalized with ethanol, m.p.
1940C, yield 45%, (C22H21ClFN3OS) required; C, (61.46%); H, (4.46%); N, (9.77%);
found; C, (61.73%); H, (4.86%);  N, (9.94%).
TLC System : Ethyl acetate : Hexane (4 : 1)
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Similarly other 5-Aryl-7-isopropyl-6-(3’-chloro,4’-fluorophenyl aminocarbonyl)-
2,3-dihydro-thiazolo[2,3-b]pyrimidine derivatives were synthesised. The physical data are
recorded in Table No.11.
[D] Antimicrobial activity of 5-Aryl-7-isopropyl-6-(3’-chloro,4’-fluorophenyl
aminocarbonyl)-2,3-dihydro-thiazolo[2,3-b]pyrimidines
Antimicrobial testing was carried out as described in [A] part-1, section-I (F).
The zone of inhibition of test solutions are recorded in graphical chart No.11.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that thiazolopyrimidine
derivatives of type-(XI) were found to be moderately active against Gram positive
bacteria B. coccus.and S. aureus,and also shown promising activity against Gram
negative bacteria like E.aerogenes and P.aeruginosa.
It has been observed that the compounds bearing  R= 4-chlorophenyl and 4-
fluorophenyl have displayed considerable activity against B. coccus. The compounds
having R= phenyl and 4-chlorophenyl have shown maximum activity against S. aureus.
In case of Gram negative bacterial strain,the significant activity was displayed by
the compounds bearing R= phenyl and 4-fluorophenyl against E.aerogenes and R= 4-methyl
phenyl and 2-nitrophenyl  against P.aeruginosa.
ANTIFUNGAL ACTIVITY
 All the compound have shown mild activity against A. niger, while the compounds
having R=4-fluorophenyl and 3-hydroxyphenyl displayed better activity.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & antifungal
activity was compared with standard drug viz. greseofulvin.
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INTRODUCTION
The term microwave was introduced just before World war-II. However, the
application of microwaves in the organic synthesis community is only now beginning to
receive widespread attention.
The first paper on the use of microwave for synthesis reactions appeared in the
open, peer-reviewed literature in 1986. Since then, over a thousand articles have been
published, numerous conferences have focused on the advances of microwave techniques,
and the use of  microwave processing is now the hot topic for combinatorial and parallel
strategies.
However, use related to MAOS, since the late 1990s has increased dramatically
to a point where it might be assumed that, in the up-coming years, most chemists will
probably use quick bursts of microwave energy.378
Microwave enhancement can take several forms. Reaction rates can be
accelerated, yields can be improved, and reaction pathways can be selectively activated
or suppressed. Fundamentally, microwaves heat things differently than conventional
means.
Microwaves Are Energy
Microwaves are a form of electromagnetic energy. Microwaves, like all
electromagnetic radiation, have an electrical component as well as a magnetic component.
The microwave portion of the electromagnetic spectrum is characterized by wavelengths
between 1 mm and 1 m, and corresponds to frequencies between 100 and 5,000 MHz.
Milestone microwave labstations use a specific, fixed frequency of 2,450 MHz (2.45 GHz).
It is useful to consider the quantum energy of microwaves in relation to other
forms of electromagnetic energy. It is important to recognize that the energy delivered
by microwaves is insufficient for breaking covalent chemical bonds. This information
can help to narrow speculation on the mechanisms for enhancement in specific reactions.
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Two Principal Mechanisms for Interaction With Matter
There are two specific mechanisms of interaction between materials and
microwaves: (1) dipole interactions and (2) ionic conduction. Both mechanisms require
effective coupling between components of the target material and the rapidly oscillating
electrical field of the microwaves.
Dipole interactions occur with polar molecules. The polar ends of a molecule
tend to align themselves and oscillate in step with the oscillating electrical field of the
microwaves. Collisions and friction between the moving molecules result in heating.
Broadly, the more polar a molecule, the more effectively it will couple with
(and be influenced by) the microwave field.
Ionic conduction is only minimally different from dipole interactions. Obviously,
ions in solution do not have a dipole moment. They are charged species that are distributed
and can couple with the oscillating electrical field of the microwaves. The effectiveness
or rate of microwave heating of an ionic solution is a function of the concentration of
ions in solution.
The interfacial polarisation, the Maxwell-Wagner effect, may also contribute
to the heating effect when the conducting particles are in contact with a non conducting
medium, e.g. in heterogenous reactions. It is particularly convenient that qualitatively
the larger the dielecric constant, the greater the coupling with microwaves. Thus solvents
such as water, methanol, DMF, ethyl acetate, chloroform, acetone, acetic acid,
dichloromethane and R-spirit are all heated when irradiated with microwaves.
Non-polar solvents like CCl4, toluene, xylene, diethylether do not couple and therefore
do not heat with microwave irradiation.
Microwave heating has emerged as a powerful technique to promote a variety of
chemical reactions. Microwave reaction under solvent-free conditions are attractive in
offering reduced pollution and offer low cost together with simplicity in processing and
handling379. The recent introduction of microwave synthesis has gained acceptance
and popularity among the synthetic chemist community & it includes virtually all types of
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chemical reactions such as Diels-Alder380, Claisen381, Vilsmeier382, Oxidation383,
Substitution384,385, Cyclisation386,387, Catalytic transfer hydrogenation388,389,
Knoevenagel condensation390, oxime synthesis391, alkylation392, decarboxylation393
etc.
Some other organic synthesis like 1,2-dihydropyridines394, phthalimide395, &
quinazolinone396 derivatives etc. are also enhanced by the microwave irradiation.
It has been reported that the rate of variety of organic reaction such as Diels
Alder397,398, Claisen reaction399,400, Oxidation401-403, Reduction404,
Diacetylation405-407, Esterification408 Hydrolysis of esters409,410, Dobenr
Condensation411, Knoevenagel   condensation412 could be enhanced by microwave
irradiation.
Detail review on “Microwave Assisted Reactions” by S. Caddick413, involves
variety of unusual chemical reactions like,
1. Aromatic Substitution Reactions
2. Alkane Functionalisation
3. Catalytic Transfer Hydrogenation
4. Oxime Synthesis
5. Radical Reactions
6. Peptide Synthesis
7. Rearrangements
8. Pericyclic Reactions
These experiments sometimes need solvents which faces some problems with
safe operation appeared and sometimes explosion results. Therefore, to solve these
problems solvent free reaction has been developed and to facilitate the scale-up of
preparative runs. Recently, reactions under dry conditions using inorganic reagents are
gaining more attention because of their enhance selectivity and milder conditions than
those associated with conventional homogenous reaction procedures. It shoud be noted
that some of inorganic additives reach temperatures in excess of 10000C very rapidly
and decomposition of materials may be problematic, therefore some precaution
regarding superheating and associated fire hazards or explosions are taken.
As a part of ongoing research towards the non-traditional approach to the
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experimental setup of organic reaction the concept of microwave enhanced reaction has
been utilized from rapid and efficient synthesis of 3-o-chlorophenyl-5,6-dihydro-6-aryl-
1,2,4-triazolo[4,5-b][1,3,4]-thiadiazoles. Q. Pro.-M Microwave oven is used as a mi-
crowave irradiation source. Conventional method and microwave technique has been
compared in terms ofyield and reaction period and data are cited in Table No. 12a.
SECTION-I :  SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-o-
   CHLOROPHENYL-5,6-DIHYDRO-6-ARYL-1,2,4-TRIAZOLO
   [ 4 , 5 - b ]  [ 1 , 3 , 4 ] -  T H I A D I A Z O L E S  B Y  C O N V E N T I O N A L
            M E T H O D
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-o-
   CHLOROPHENYL-5,6-DIHYDRO-6-ARYL-1,2,4-TRIAZOLO
   [4,5-b][1,3,4]-THIADIAZOLES BY MICROWAVE METHOD
198Microwave induced.......
SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-o-CHLORO PHENYL-
5,6-DIHYDRO-6-ARYL-1,2 ,4-TRIAZOLO[4,5-b] [1,3,4]- THIADIAZOLES BY
CONVENTIONAL METHOD
Dihydrothiadiazoles play a vital role owing to their wide range of pharmacological
activity with a view to getting better therapeutic agents and to evaluate its pharmacological
profile different types of dihydrothiadiazole derivatives of type-(XII),  prepared by the
condensation of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole with different
aromatic aldehydes in presence of  p-toluenesulphonic acid.
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
N N
N
N
H
S
R
Cl
Type-(XII)     R = Aryl
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N N
N
NH2
SH
Cl
O
NH NH2
Cl
O
NH NH
S
SKCl
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
N N
N
N
H
S
R
Cl
R-CHO
p-TsOH
DMF
REACTION SCHEME
        Type - (XIII)          R=Aryl
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-o-CHLOROPHENYL-5,6-DIHYDRO-6-(p-ANISYL)-
1 , 2 , 4 - TRIAZOLO[3,4-b] [1,3,4]- THIADIAZOLE
 Observed
Alkane C-H str. (asym.) 2924 2975-2950 420
-CH3 C-H str. (sym.) 2874 2880-2860 “
C-H i.p.def. (asym.) 1495 1470-1435 “
C-H o.o.p. def. (sym.) 1353 1390-1370 “
Aromatic C-H  str. 3054 3080-3030 421
C=C str. 1559 1585-1480 “
C-H i.p. def. 1128 1125-1090 “
C-H o.o.p. def.   817   835-810 “
Triazole C=N str. 1604 1612-1593 420
moiety C-N str. 1232 1350-1200 424
N-N str. 1047 1050-1010 421
Thiadiazole N-H str. 3419 3450-3200 “
N-H def. 1604 1650-1580 “
                                               (overlapped)
C-S-C str.  665                    720-570 422
Ether C-O-C str. (asym.) 1232 1275-1200 “
                                               (overlapped)
C-O-C str. (sym.) 1047 1075-1020 423
                                     (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N N
N
N
H
S
O
CH3
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 3-o-CHLOROPHENYL-5,6-DIHYDRO-6-(p-METHOXY)-
1 , 2 , 4 - TRIAZOLO[3,4-b] [1,3,4]- THIADIAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.84 3H singlet Ar-OCH3                     -
2. 6.89-6.91 2H doublet Ar-Hee’ Jef-9.48
3. 7.38-7.41 1H multiplet Ar-Hc       -
4. 7.48-7.50 2H multiplet Ar-Hb+d       -
5. 7.53-7.55 1H doublet Ar-Ha       -
6. 7.65-7.67 2H doublet Ar-Hff’ Jfe-9.52
7. 9.90 1H singlet -CHg                      -
8. 10.8 1H singlet -NHh         -
N N
N
N
H
S
Cl
O CH3
a
b
c
d
e
f
e'g
f'h
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EXPANDED AROMATIC REGION
N N
N
N
H
S
Cl
CH3
MASS SPECTRUMN
N
N
NH S
Cl
O
CH3
ab
c
d
e
f
e'
g
f'
h
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SECTION - II
S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F 3 - o-CHLORO
P H E N Y L - 5 , 6 - D I H Y D R O - 6 - A R Y L - 1 , 2 , 4 - TRIAZOLO[4,5-b][1 ,3 ,4]-
THIADIAZOLES BY MICROWAVE IRRADIATION
As a part of our research programme towards the non traditional approach to
the experimental set up of organic reactions, the concept of “Microwave induced
Organic Reaction Enhancement” (MORE) chemistry has been utilised for rapid
and efficient synthesis of some dihydrothiadiazoles which is described as under.
The synthesis was carried out by condensation of 3-mercapto-4,N-amino-5-O-
chlorophenyl-1,2,4-triazole with different aromatic aldehydes in the presence of
p-toluenesulphonic acid using microwave irradiation.
Various preparations of the dihydrothiadiazoles by microwave irradiations are
available in literature.414-419
The constitution of the synthesised products have been supported by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz was used as a microwave irradiation
source and data are compared in terms of yield and reaction period and has been cited
in Table No. 12a.
Type-(XII)    R = Aryl
N N
N
N
H
S
R
Cl
N N
N
NH2
SH
Cl
R-CHO, P-Ts-OH
DMF
microwave irradiation 
8-10 mins.
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TABLE NO. 12a   :  COMPARISON OF CONVENTIONAL METHOD AND
MICROWAVE INDUCED SYNTHESIS OF 3-o-CHLORO
PHENYL-5,6-DIHYDRO-6-ARYL-1,2,4-TRIAZOLO[4,5-
b][1,3,4]-THIADIAZOLES
Comp.
  No.
R Thermal Microwave M. P.
 oCReaction
Period (hrs.)
Yield
  %
Reaction
Period (min.)
  12a 4-OCH3-C6H4- 12 72 10 78 132
12b 4-CH3-C6H4- 13 64 8 72 188
12c 4-OH-C6H4- 11 54 11 65 106
12d 4-Cl-C6H4- 14 58 12 70 156
12e 4-F-C6H4- 12 66 9 76 164
12f 3-OH-C6H4- 14 48 10 62 138
12g 2-Cl-C6H4- 13 69 11 77 142
12h 2-OH-C6H4- 14 56 8 73 204
12i 2-NO2-C6H4- 13 61 12 69       122
12j 2,4-(Cl)2-C6H3- 11 70 11 82 118
12k 3,4-(OCH3)2-C6H3- 14 64 10 72 108
12l anthranyl- 11 50 12 67 152
Yield
  %
CONCLUSION
We have demonstrated a rapid and general synthesis of 1,3,4-dihydro thiadiazoles
using a variety of aromatic aldehydes with heating in a microwave oven which can be
considered as a step towards Green Chemistry. Consequently, reactions exhibit cleaner
products and more facile work-up procedures. The method affords high yields of the
desired products in remarkably short reaction times   decreased to 8-10 min. from 10-
14 hrs. and improve reproducibility. The reaction conditions are sufficiently mild to be
employed for the construction of the heterocyclic thiadiazole system and suitable for high
throughput synthesis of the compounds.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-o-CHLORO PHENYL-
5,6-DIHYDRO-6-ARYL-1,2,4-TRIAZOLO[4,5-b][1,3,4]-THIADIAZOLES
(A) Synthesis of Potassium-o-chlorophenyl dithiocarbamate101
See [A] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole
See [A] Part-I, Section-I (D).
SECTION-I
(A) Synthesis of  3-o-chlorophenyl-5,6-dihydro-6-p-anisyl-[1,2,4]-triazolo
[4,5-b][1,3,4]-thiadiazole by conventional method.
A mixture of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole (2.26g, 0.01 M),
p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene sulphonic acid (50 mg)
was refluxed for 12 hrs. The reaction mixture was poured onto crushed ice. The product
was isolated and crystallised from ethanol. Yield 72%, m.p. 132oC, (C16H13ClN4OS)
: Required : C, 55.73; H, 3.80; N, 16.25; Found : C, 55.87; H, 3.96; N, 16.36%).
TLC solvent system : Acetone : Benzene (3 : 7).
Similarly  other derivatives were synthesised. The physical data are recorded in
Table No. 12.
(B) Antimicrobial activity of 3-o-chlorophenyl-5,6-dihydro-6-aryl-1,2,4-
triazolo-[4,5-b][1,3,4]-thiadiazoles.
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (F). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 12.
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SECTION - II
(A) Synthesis of 3-O-chlorophenyl-5,6-dihydro-6-p-anisyl-1,2,4-triazolo
[4,5-b][1,3,4]-thiadiazoles by microwave method.
A mixture of 3-mercapto-4,N-amino-5-o-chlorophenyl-1,2,4-triazole (2.26 g, 0.01 M),
p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene sulphonic acid (50 mg)
was irradiated in a microwave oven for 8-10 min at 280 watts. The contents were cooled
and poured onto crushed ice. The product was isolated and crystallised from ethanol.
Yield 78%, m.p. 132oC.
Similarly other derivatives have been synthesised.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
 From the experimental data it has been concluded that all the dihydrothiadiazoles
of type-(XII) were mild to moderately active against different strains of Gram positive
and Gram negative bacteria.
It was observed that the compound show good activity against Gram positive
bacteria, maximum activity was observed in compound bearing R=4-chlorophenyl against
B.coccus. Compound bearing R=4-fluorophenyl was active against S.aureus. The
significant activity was observed in compound bearing R=4-fluorophenyl against
E.aerogenes, while the compounds bearing R=4-chlorophenyl and 2,4-dichlorophenyl
fairly inhibit the growth of P.aeruginosa.
ANTIFUNGAL ACTIVITY
It has been found that all the compounds exhibited mild activity against A.niger
and compounds bearing R=2,4-dichlorophenyl and 4-methylphenyl  showed good activity
against A.niger.
The antibacterial activity was compared with standard drugs viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.
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